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ABSTRACT 
Catherine A. Siler:  The Role of LCV and EBV Latent Membrane Protein 2A in Epithelial 
Cells 
(Under the direction of Nancy Raab-Traub) 
 
Epstein-Barr Virus (EBV) is a ubiquitous human herpesvirus that is associated with 
malignancies of both lymphoid and epithelial origin including Burkitt’s lymphoma and 
nasopharyngeal carcinoma (NPC) among others.  The focus of this study was to investigate 
both EBV and rhesus EBV (LCV) latent membrane protein 2A (LMP2A) signaling and 
biological functions in epithelial cells and their contribution to EBV-mediated 
carcinogenesis. 
 Rhesus LCV LMP2A (Rh-LMP2A) has an overall sequence homology of 62% to 
EBV LMP2A.  The 12 transmembrane domains and the N-terminal cytoplasmic domain 
containing an immunoreceptor tyrosine-based activation motif (ITAM) and PY motifs are 
conserved in Rh-LMP2A.  In this study, Rh-LMP2A expression in human foreskin 
keratinocytes (HFK) activated Akt and inactivated GSK3β.  This led to the subsequent 
accumulation and nuclear translocation of β-catenin which was found to be Akt dependent.  
Rh-LMP2A also inhibited epithelial cell differentiation.  A mutant form of Rh-LMP2A 
lacking the last six transmembrane domains was able to function similarly to full-length Rh-
LMP2A. 
 Since EBV LMP2A is consistently expressed in metastatic NPC, the potential role of 
LMP2A in metastasis was investigated.  EBV LMP2A expression in HFK cells led to 
increased expression and activity of several matrix metalloproteinases (MMPs), which are 
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involved in basement membrane and extracellular matrix degradation.  The activity of MMP-
7 and MMP-13 was dependent on Akt activation, whereas MMP-2 activity was dependent on 
MAPK activation.  These results identify a mechanism by which EBV LMP2A could 
contribute to NPC metastasis. 
 Through the activation of the PI3K/Akt and β-catenin pathways that impact cell 
proliferation and survival in addition to upregulating MMP expression and activity, LMP2A 
likely contributes to carcinogenesis and metastasis.  Lastly, the similarity of rhesus LCV to 
EBV further validates the rhesus macaque model for the study of EBV pathogenesis. 
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Epstein-Barr Virus 
 Denis Burkitt first identified a novel extranodal lymphoma occurring in children in 
equatorial Africa where malaria was also endemic in the 1940s (24-28).  Burkitt 
hypothesized the involvement of an additional infectious agent due to the atypical 
epidemiological and clinical presentation of the lymphomas (24, 27, 28).  Epstein-Barr virus 
(EBV) was first identified by Epstein, Achong, and Barr in 1964 using electron micrographs 
of Burkitt’s lymphoma cells grown in culture showing a herpesvirus-like particle that did not 
react to antibodies from other known herpesviruses and was unable to replicate in cultured 
cells(71). 
 EBV, also known as human herpesvirus 4, is a ubiquitous gamma herpesvirus within 
the lymphocryptovirus genus (275).  It is an enveloped virus with a large double-stranded 
DNA genome of 184 kilobase pairs (12).  EBV is a successful human pathogen as over 90% 
of the global adult human population is infected with the virus (127).  As with all 
herpesviruses, EBV infection remains for the life of the host and humans are the only known 
host for EBV (275).  EBV infection is typically asymptomatic and does not induce disease in 
the host, however, in certain contexts such as immunosuppression, EBV is associated with 
several pathologic conditions.  The virus exhibits tropism for both B lymphocytes and 
epithelial cells (7, 275).  Of note, the defining characteristic of lymphocryptoviruses is the 
ability to immortalize B lymphocytes in vitro which are known as lymphoblastoid cell lines 
(LCLs) in the case of EBV (128).  In B lymphocytes, the virus can enter a latent state to 
enable its persistence and evade immune detection as well as undergo a productive infection 
with lytic replication resulting in virion assembly and release (10).  Both lytic and latent 
infection of epithelial cells can occur with latent infection contributing to the development of 
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EBV-associated epithelial cancers.  In addition to B lymphocytes and epithelial cells, 
numerous reports have shown infection in other cell types such as natural killer (NK) cells, T 
cells, monocytes, and neutrophils (114, 147, 151, 290, 306, 326, 338). 
 
EBV Life Cycle 
 EBV is transmitted through saliva that contains both cell-free virus as well as infected 
cells that ultimately leads to the infection of the oral epithelium (279).  One early study 
suggested that EBV infection of a host commenced with the fusion of EBV positive B 
lymphocytes to epithelial targets (15).  Although this study had not been confirmed nor 
refuted to date, infection of epithelial cells is more efficient when in close proximity with 
virus producing B lymphocytes than cell-free virus (146, 332).  Infection of the oral 
epithelium can lead to progeny production through lytic replication in oral epithelial cells 
(187, 188, 299).  Released virions can subsequently infect circulating B lymphocytes in the 
oral epithelium or in various lymphoid organs (10, 230, 243).  Naïve and memory B cells are 
equally susceptible to EBV infection in vitro (355).  Notably, viral attachment and entry 
differs between epithelial cells and B lymphocytes. 
 EBV attachment to B lymphocytes involves high affinity binding between the 
gp350/220 viral envelope glycoprotein and the CD21 cellular receptor to initiate endocytosis 
of the virus into the host cell (80, 86, 234, 242, 317).  This action leads to viral fusion with 
the endosomal membrane at a low pH (226).  Conversely, the role of CD21 in epithelial cell 
EBV infection remains unclear and indicates a different mechanism is involved in EBV 
attachment and entry of epithelial cells.  EBV lacking the gH and gL viral proteins is unable 
to bind several epithelial cell lines, although the cellular receptor has not yet been identified 
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(232, 245).  A recent report showed the EBV glycoprotein BMRF2 interacts with the α5β1 
integrin on epithelial cells and antibodies against the integrin and BMRF2 partially blocked 
viral binding (332).  In contrast to EBV infection B lymphocytes, endocytosis is not required 
for epithelial cell entry and fusion occurs at a neutral pH (279).  Notably, EBV produced 
from human leukocyte antigen (HLA) class II negative epithelial cells can infect B 
lymphocytes more readily than virus produced from HLA class II positive B lymphocytes.  
In addition, virus produced in B lymphocytes can infect epithelial cells more readily than 
virus produced in epithelial cells (17, 279). 
 Once EBV enters B lymphocytes, the viral genome circularizes to form a viral 
episome and initiates a limited latency program through transcription from the viral Wp 
promoter using cellular RNA polymerase II (289).  Latently infected B lymphocytes have a 
restricted repertoire of viral gene products which promotes evasion from the immune system 
(11, 230, 320, 323).  Latently infected B lymphocytes periodically undergo reactivation 
which leads to the production of new viral progeny (7, 10).  The newly formed virus is 
released and can infect surrounding B lymphocytes or oral epithelial cells.  Additionally, the 
virus can be shed through saliva, allowing for transmission to the next host.  A schematic 
illustration of the EBV life cycle can be seen in Figure 1. 
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Figure 1.  The EBV Life Cycle.  Virus enters the oral cavity through saliva and may 
lytically infect cells of the oral epithelium.  Resulting progeny access the B cell compartment 
by infecting B lymphocytes circulating nearby.  Once B cells are infected, the virus can enter 
a latent form with limited expression of viral genes.  Periodically, these latently infected B 
cells can reactivate and the lytic program results in the release of progeny.  Reactivation of B 
cells near oral mucosal sites may lead to lytic infection of the oropharyngeal epithelial cells, 
thus allowing progeny virus to be shed back out into the saliva, allowing for horizontal 
transmission to a new host. 
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Lytic Infection 
 In order to study EBV lytic replication, latently infected cells must be induced to 
enter the lytic program.  Studies in vitro have focused on inducing lytic replication in latently 
infected cells through the use of phorbol esters.  Phorbol esters induce lytic replication by 
activating the protein kinase c (PKC) pathway.  The PKC pathway induces lytic replication 
via the activation of AP-1 sites located upstream of the viral immediate-early (IE) genes and 
through the activation of the BZLF1 protein (8, 83, 84).  Lytic replication can also be 
induced through the activation of the B cell receptor (BCR) with soluble immunoglobulin 
(315).  Once induced, cells undergo cytopathic changes prior to virion release including 
margination of nuclear chromatin, inhibition of host molecular synthesis, replication of viral 
DNA, assembly of nucleocapsids, nucleation of nucleocapsids, and envelopment of the virus 
through the inner nuclear membrane (56, 102, 107, 168, 254, 275, 290).  Lytic EBV 
infection, as with other herpesviruses, follows a temporal and sequential order and can be 
divided into the immediate early, early, and late phases of gene expression.  
 
Immediate Early Genes 
 The immediate early proteins BZLF1 and BRLF1, designated as such by their 
expression in the presence of protein synthesis inhibitors such as cycloheximide, serve as 
viral transactivators to initiate the events of lytic infection and are necessarily located in the 
nucleus (85, 271, 315, 357).  With this, expression of either protein during latency will lead 
to the induction of the other and the virus will enter the lytic cycle (50, 111, 121, 272, 302).  
Both BZLF1 and BRLF1 activate transcription of early gene promoters to secure progression 
of the lytic cycle and BZLF1 also downregulates the Cp promoter controlling expression of 
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the latent EBNA genes, thereby ensuring the effective switch from latency to the lytic cycle 
(23, 41, 121, 135, 171, 198, 200).   Additionally, BZLF1 is required for viral DNA 
replication and BRLF1 enhances viral replication efficiency (81, 291).  BZLF1 also has 
important activities which allow the virus to evade the immune system such as the 
downregulation of tumor necrosis factor receptor 1 and interferon gamma receptor, making 
the host cell unresponsive to immunostimulatory cytokines (238, 239). 
 
Early Genes 
 The EBV early genes are designated as such because their expression requires protein 
synthesis, but viral replication is not required for their expression.  The early genes encode a 
myriad of proteins involved in the modulation of gene transcription and viral DNA 
replication, among others (82).  The EBV genome is replicated during the lytic cycle by a 
viral DNA polymerase encoded by BALF5 (161).  Notably, another early protein, BHRF1, is 
highly homologous to cellular Bcl-2 (125, 354).  Cellular Bcl-2 is located in the mitochondria 
and plays a critical role in protecting the cell from apoptosis.  Interestingly, the bcl-2 locus is 
activated by chromosomal translocation which is characteristic of several types of follicular 
B-cell lymphomas (329-331).  This suggests the EBV Bcl-2 homolog, BHRF1, may act to 
protect infected cells from undergoing apoptosis until the replication cycle including virion 
assembly and release is complete. 
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Late Genes 
 Late genes typically encode structural components of the virion, such as tegument 
proteins and glycoproteins.  The primary EBV glycoproteins, gp350/220 and gp42, are 
encoded by the late BLLF1 and BZLF2 genes, respectively.  They serve as binding partners 
for the CD21 cellular receptor and major histocompatibility complex (MHC) class II receptor 
on B lymphocytes mediating viral entry (80, 192, 275).  In the case of epithelial cells, the 
cellular receptor(s) responsible have not yet been identified.  However, a recent report has 
implicated integrins in viral entry of epithelial cells (332).  Another late gene, BCRF1, 
encodes a viral homolog to human IL-10 (140, 233).  As with human IL-10, BCRF1 has 
negative immunomodulatory functions by decreasing responses from NK cells, T cells, and 
macrophages (287, 309).  The late phase of the lytic cycle concludes with virion assembly 
and egress, typically about four days after productive infection or the onset of reactivation. 
 
Establishment of Latency 
 EBV latency is characterized by the constitutive expression of specific subsets of 
viral genes.  These latent genes include the six EBV nuclear antigens (EBNAs 1, 2, 3, 3A, 
3B, 3C, and LP) and three latent membrane proteins (LMPs 1, 2A, and 2B), as well as a 
group of spliced 3΄ transcripts, BamHIA transcripts known as BARTs, and small non-
polyadenylated RNAs known as EBER1 and EBER2.  As seen in Table 1, latency is 
categorized into three different types depending on gene expression patterns.  During Type I 
latency, viral gene expression is quite limited.  Only EBNA1 is expressed at the protein level 
along with transcripts for the BARTs and EBERs.  This type of latency is characteristic of 
viral expression in endemic Burkitt’s lymphoma.  Type II latency, which is characteristic of 
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EBV-associated Hodgkin lymphoma and nasopharyngeal carcinoma (NPC), exhibits 
expression of EBNA1, LMP1, 2A, and 2B, and transcription of the EBERs and BARTs.  In 
Type III latency, EBNA 1, 2, 3A-C, and LP, as well as LMP1, 2A, 2B, the EBERS and 
BARTs are all expressed.  Type III latency is typical of LCLs established by in vitro 
infection of primary B cells with EBV and of post-transplant lymphoproliferative disease 
(PTLD) in vivo (20).  EBV-mediated transformation of B lymphocytes is dependent on a 
group of latent proteins including EBNA1, 2, 3A, 3C and LMP1 (47, 270). 
Latency Type Viral products expressed Associated Diseases
Type I
Type II
Type III
EBNA1, BARTs, EBERs
EBNA1, BARTs, EBERs, 
LMP1, LMP2A, LMP2B, 
+/- BARF1
EBNA1, 2, 3A-C, and 
LP, BARTs, EBERs, 
LMP1, LMP2A and 2B
Burkitt’s Lymphoma
Hodgkin Lymphoma, 
Nasopharyngeal 
Carcinoma, Gastric 
Carcinoma
Lymphoblastoid cell 
lines, post-transplant 
lymphoproliferative
disease
 
Table 1.  EBV Latency Expression Patterns 
 
EBNA1 
 EBNA1 is a nuclear protein that is expressed in each type of latency with its principal 
role being the maintenance and replication of the viral genome through specific binding to 
the origin of plasmid replication known as oriP (273, 355).  Through the tethering of the viral 
episome to mitotic chromosomes in dividing cells, each daughter cell retains the viral 
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genome (246, 350, 351).  EBNA1 can also regulate the transcription of itself and the other 
EBNAs, as well as LMP1 through its interaction with viral promoters (355).  EBNA1 
contains glycine-alanine repeats between the amino- and carboxy-terminal ends which 
stabilizes the protein by preventing proteasomal degradation (190).  EBNA1 expression in 
murine cells does not elicit a CTL response as a result of its lack of proteasomal breakdown 
which is required for antigen processing and presentation by MHC class I (190, 327).  These 
unique characteristics of EBNA1 allow latently infected cells, particularly those with a Type 
I expression pattern, to avoid immune recognition by the host. 
 
EBNA2 and EBNA-LP 
 Although both EBNA2 and EBNA-LP are expressed during Type III latency, only 
EBNA2 is essential for the transformation of B lymphocytes by EBV.  EBNA-LP is not 
essential, but is assists in the outgrowth of LCLs (4, 48, 212).  EBNA-LP has two runs of 
basic amino acids that facilitate its nuclear translocation where is coactivates EBNA2-
mediated transcription from the Cp and LMP1 promoters (120, 244, 259).  Moreover, 
EBNA-LP is a phosphoprotein, and its phosphorylation status and function may be cell cycle 
dependent (167, 175).  EBNA-LP can also interact with several cellular proteins such as Rb, 
p53, and p14ARF (165, 313).  The role of EBNA-LP in cell cycle progression may occur 
through these interactions with tumor suppressors, but the importance of these interactions in 
LCLs remains undetermined.  Additionally, EBNA-LP interacts with the viral Bcl-2 
homolog, BHRF1, indicating a possible role in modulating apoptosis (119, 216).  These 
functions of EBNA-LP underscore the importance of EBNA-LP in the establishment of viral 
latency and cellular transformation. 
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 EBNA2 is similar to the cellular Notch protein and is a potent viral transactivator of 
both viral and cellular promoters via its interaction with recombination signal sequence-
binding protein (RBP)-Jκ in the nucleus (112, 139, 158).  Through this interaction, EBNA2 
induces cellular genes such as CD21, CD23, c-fgr and c-myc in addition to EBV LMP1 and 
LMP2A and is critical for EBV transformation of B lymphocytes (1, 49, 75, 76, 337, 348).  
 
EBNA3A, EBNA3B, and EBNA3C 
 As with EBNA2 and EBNA-LP, the EBNA3s are only expressed in Type III latency.  
EBNA3B is not necessary for B lymphocyte transformation and not required for lytic 
replication, LCL outgrowth, or cell survival (324).  In contrast, EBNA3A and 3C along with 
LMP1 are essential for EBV-mediated B lymphocyte transformation (325).  Even though the 
EBNA3 mRNAs are present at very low levels, the protein products exhibit a long half life 
(173).   
 The EBNA3s negatively regulate the transcriptional activation of EBNA2 and 
EBNA-LP through competition for Notch and RBP-Jκ (159, 179, 213, 278, 280, 333, 359).  
EBNA3A can repress the viral Cp promoter in both epithelial cells and B lymphocytes (45).  
EBNA3C cooperates with RAS to disrupt cell cycle checkpoints and induces rodent 
fibroblast transformation (255, 256).  In conjunction with EBNA2, EBNA3C can induce 
LMP1 transcription through the binding of the PU.1 site within the LMP1 promoter (213, 
360). 
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BARTs 
 BamHIA rightward transcripts (BARTs) are a group of abundantly expressed and 
highly spliced RNAs that can be detected in all EBV-associated cancers and in all types of 
latency as well as in the lytic cycle (20, 37, 104, 105, 133, 164, 221, 257, 258).  Although the 
BARTs are ubiquitously expressed in all types of latency, they are not necessary for EBV-
mediated transformation of B lymphocytes in vitro (281).  Three BART transcripts have been 
of interest as they appear to encode open reading frames, rkbarf0, rb2, and rk103, with RK-
BARF0 and RB2 mRNAs being the most plentiful in NPC (285). 
 RK-BARF0 binds Notch 1 and Notch 4 as well as induces the nuclear translocation of 
unprocessed Notch (183).  Notably, RK-BARF0 also induces the proteasomal degradation of 
Notch which correlates with reduced levels of Notch in EBV positive cell lines (321).  
RK103 binds RBP-Jκ and inhibits the transactivating activities of both Notch1C and EBNA2, 
and RB2 can bind the receptor for activated protein kinase C (RACK) (301, 358).  BARF1, 
another BART product, is a secreted protein and exhibits oncogenic activity when expressed 
in rodent fibroblasts (57, 298). 
 Recent reports have shown that EBV encodes at least 17 micro RNAs (miRNAs) with 
14 of them found in BARTs (31, 113, 260).  The BART miRNAs are expressed in Type III 
latency with high levels detected in infected epithelial cells and reduced levels in infected B 
lymphocytes and virtually undetectable in epithelial cells and B cells in Type I or Type II 
latency (31, 176).  Notably, the induction of lytic replication enhances the expression of 
many viral miRNAs. These novel findings indicate a potential mechanism by which EBV 
could regulate host gene expression without viral gene expression, thereby further eluding 
immune surveillance.  
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EBERs 
 EBER1 and EBER2 are small non-polyadenylated RNAs that are the most copious 
RNAs in latently infected cells.  Although present in all types of latency, they are not 
required for EBV-mediated transformation of B lymphocytes (310).  Since the EBERs are 
expressed in most EBV-associated cancers, they form the basis of an in situ hybridization 
assay to detect EBV infection in tissues (14, 116, 138, 257, 258).  Currently, the function of 
the EBERs remains unclear, however, one report details EBER-mediated induction of 
insulin-like growth factor 1 (IGF-1) leading to enhanced proliferation of EBV positive gastric 
carcinoma cells (153).  EBERs have also displayed oncogenic characteristics when expressed 
in EBV-negative Burkitt’s lymphoma cell and rodent fibroblasts and confer properties such 
as anchorage-independent growth and tumorigenicity in immunodeficient mice (178, 194, 
349).  Additionally, the EBERs can also confer resistance to apoptosis in Burkitt’s lymphoma 
and other B cell lines through binding and inhibiting the double-stranded RNA-activated 
protein kinase (PKR), a known protein synthesis inhibitor and putative tumor suppressor 
(241, 296, 349). 
 
LMP1 
 LMP1, which is expressed in latency Types II and III, is the primary EBV oncogene 
as it can transform rodent fibroblasts in vitro and is essential for EBV-mediated 
transformation of B lymphocytes (169, 335).  LMP1 expression in epithelial cells drastically 
alters cell growth, induces morphologic changes, and inhibits differentiation (53, 76).  LMP1 
expression in cells has a multitude of effects resulting in the induction of a variety of cellular 
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proteins such as cell adhesion molecules (ICAM1 and E-cadherin), anti-apoptotic proteins 
(Bcl-2 and A20), and growth factors (EGFR) (67, 68, 90, 126, 228, 336). 
 LMP1 contains two major signaling domains at the carboxy-terminus known as 
carboxy-terminal activating region 1 (CTAR1) and carboxy-terminal activating region 2 
(CTAR2).  Although LMP1 is not particularly homologous to any other known protein, it 
functions in a similar manner to the tumor necrosis factor receptor (TNFR) and CD40 (240).  
Both CD40 and LMP1 signal by recruiting adapter proteins called TNFR associated factors 
(TRAFs) to their respective PxQxT motifs (60, 89).  While CTAR1 recruits TRAFs 1, 2, 3, 
and 5 directly through its PxQxT motif, CTAR2 indirectly recruits TRAFs 2 and 6 by 
binding adapter proteins such as the TNFR associated death domain (TRADD), the receptor 
interacting protein (RIP), and BS69 (154, 155, 334).  Unlike TNFR, LMP1 does not require a 
ligand to associate with the TRAFs, thereby allowing LMP1 to be constitutively active (60, 
89, 227, 240). 
 LMP1 can activate a multitude of signaling pathways including NFκB, Cdc42, p38, c-
jun N-terminal kinase (JNK), phophoinositol 3-kinase (PI3K), and the mitogen-activated 
protein kinase (MAPK)/extracellular signal-regulated (ERK) 1 (MEK1) pathway (54, 69, 70, 
118, 199, 251, 277, 286).  LMP1 also upregulates cell surface expression of a myriad of 
markers including CD23, CD39, CD40, CD44, ICAM1, MHC class II, and LFA3.  
Additionally, it can also induce cellular secretion of IL-10 and downregulate CD10 levels 
(173).  LMP1 inhibits apoptosis in B lymphocytes as well as protects epithelial cells from 
p53-mediated apoptosis by increasing levels of A20 and Bcl-2 in the cell (90, 91, 110, 126, 
214, 284). 
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 LMP1 can induce expression the inhibitor of differentiation (Id) family of proteins as 
well as deregulate an array of markers associated with cell cycle progression (73, 191, 279).  
LMP1 expression in epithelial cells blocks cellular differentiation (53).  In transgenic mice, 
LMP1 expression in the skin induces epidermal hyperplasia and when expressed under the 
control of the immunoglobulin heavy chain promoter, increases the incidence of B cell 
lymphomas (180, 345). 
 
LMP2A and 2B 
 LMP2A and 2B are splice variants that are transcribed across the fuses terminal 
repeats of the EBV episome.  Therefore, latent infection and genome circularization are 
required for their expression.  Transcription of LMP2A and 2B are initiated from two 
different promoters, with differences in the first exons of the two proteins.  LMP2A is a 12 
pass transmembrane protein with a 119 amino acid cytoplasmic N-terminus and a short 27 
amino acid C-terminus tail.  LMP2B lacks the N-terminal 119 amino acids present in 
LMP2A, however, the remainder of LMP2B is identical to LMP2A.  In EBV infected B 
lymphocytes, LMP2A and 2B are expressed in the plasma membrane and colocalize with 
LMP1 in lipid rafts (63, 131, 203).  In epithelial cells, LMP2A and 2B expression exhibits 
perinuclear localization and colocalizes with the endoplasmic reticulum, golgi complex, 
lysosome, and late endosome (52, 209).  With these disparate expression patterns, it is likely 
LMP2A signaling may have different mechanisms and outcomes in B lymphocytes in 
comparison with epithelial cells.  In a similar fashion to LMP1, LMP2A in the plasma 
membrane can oligomerize, and the clustering signal required for this is located at its C-
terminus (215).  Currently, the function of LMP2B is unknown, however, it is possible that 
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LMP2B may serve to limit LMP2A signaling by complexing with LMP2A at the plasma 
membrane and reducing the LMP2A contacts needed for signaling (202).  LMP2B is 
conserved in the rhesus homolog, rhesus lymphocryptovirus, suggesting LMP2B has an 
important, but currently unknown function (276). 
 LMP2A expression is not required for EBV-mediated immortalization of B 
lymphocytes in vitro, but in vivo infection efficiency may be enhanced by the presence of 
LMP2A (19, 174, 204-206, 282).  In latently infected B lymphocytes, LMP2A expression is 
critical for the maintenance of latency.  It blocks the B cell receptor (BCR) activation and 
signaling through several approaches (222-225).  This BCR block is important in maintaining 
latency as events downstream of B lymphocyte activation lead to the reactivation of the EBV 
lytic cycle (222, 224). 
 LMP2A blocks BCR signaling by several different methods.  In a normal cell, antigen 
binds and the BCR translocates into lipid rafts where the necessary signaling molecules 
needed for its function are located.  However, in an EBV infected cell, LMP2A blocks this 
antigen-stimulated relocation of the BCR to lipid rafts (63).  In addition, LMP2A blocks 
antigen processing downstream of binding to the BCR by an other unknown mechanism (63).  
LMP2A also absorbs molecules typically utilized by the BCR such as Lyn and Syk kinases 
and mediates their turnover so they are unavailable for BCR signaling (93, 94, 143, 222, 223, 
225). 
 The N-terminus cytoplasmic domain of LMP2A contains several important motifs 
that are critical for its signaling functions in both B lymphocytes and epithelial cells.  The N-
terminus cytoplasmic domain contains eight tyrosine residues, of which five have roles in 
LMP2A signaling.  Tyrosines at residues 74 and 85 are part of an immunoreceptor tyrosine-
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based activation motif (ITAM).  The Igα/β chains of the BCR also have ITAM motifs, and it 
is through these ITAMs that the BCR is able to bind and activate Syk, a kinase that can then 
recruit and activate other effector molecules.   Phosphorylation of the ITAM tyrosine 
residues is important for BCR activity, and other kinases such as Lyn are able to 
phosphorylate these residues upon BCR translocation to lipid rafts.  The phosphorylated 
ITAM of LMP2A can also bind the SH2 domains of Syk, and tyrosine 112 of LMP2A binds 
Lyn.  Lyn phosphorylates the ITAM of LMP2A, and through the binding of Syk, LMP2A 
uses its ITAM to control downstream signaling in B lymphocytes.  Ultimately, LMP2A 
renders B lymphocytes less responsive to antigen stimulation. 
 LMP2A can also manipulate the turnover of BCR signaling molecules through its 
association with ubiquitin ligases.  LMP2A contains two PPPPY motifs involving tyrosines 
60 and 101 that facilitate binding to members of the Nedd4 ubiquitin ligase family through 
the WW domains of the ligases (143, 346).  This association in B lymphocytes leads to 
increased degradation of LMP2A, Lyn, and potentially Syk (143, 144, 346).  Interestingly, 
the PY motifs of LMP2A are not required for its block of B cell signal transduction (144, 
311).  However, the LMP2A ITAM motif and Lyn binding site at tyrosine 112 are critical for 
the inhibition of BCR activation and signaling (92-94). 
 In addition to blocking the BCR, LMP2A has other important functions in B 
lymphocytes as seen with transgenic mouse model studies (33).  Transgenic mice were 
generated to direct LMP2A expression to cells of a B lymphocyte lineage by inserting the 
LMP2A transgene under the control of the immunoglobulin heavy chain promoter and 
enhancer.  In the B lymphocytes of these mice, LMP2A interferes with normal B cell 
development processes.  For example, LMP2A blocks immunoglobulin heavy chain 
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rearrangement and leads to changes in cell surface markers (33).  Notably, LMP2A 
expressing B lymphocytes from these transgenic mice are able to circumvent normal B cell 
developmental checkpoints, and immunoglobulin negative B cells are then able to leave the 
bone marrow and colonize the periphery (32, 33).  The LMP2A ITAM motif is crucial for its 
ability to manipulate these developmental and survival signals in the transgenic B 
lymphocytes, and the activation of Bruton’s tyrosine kinase (Btk) has been associated with 
some of these effects (219, 220).  Additionally, microarray analysis revealed that the 
transgenic B cells have global downregulation of genes involved in B cell development and 
the transcription factors that regulate them, such as E2A and its target Pax-5 (265). 
 In addition to affecting B lymphocyte signaling, LMP2A has also been shown to 
affect signaling in epithelial cells.  In epithelial cells, LMP2A phosphorylation is triggered by 
cell adhesion to extracellular matrix proteins such as fibronectin, and the Src family kinase 
inhibitor C-terminal Src kinase (Csk) has been implicated in this event (293).  Furthermore, a 
putative Csk binding motif has been identified which involved tyrosine 101 of the LMP2A 
N-terminal (293).  LMP2A has also been shown to activate PI3K kinase and its target Akt in 
both B cells and epithelial cells (237, 292, 312).  Notably, some epithelial cell lines 
expressing LMP2A exhibit oncogenic properties.  LMP2A expression in the HaCaT human 
keratinocyte cell line conferred anchorage-independent growth in soft agar and gave rise to 
poorly differentiated, highly metastatic tumors when injected into nude mice (292).  Colony 
formation in soft agar was PI3K signaling dependent, as it was inhibited by treatment with 
LY294002, a PI3K inhibitor. 
 LMP2A can also activate ERK, JNK and Syk in epithelial cells (39).  Activation of 
these pathways resulted in enhanced migration in LMP2A expressing epithelial cells, and 
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treatment with ERK or Syk inhibitors abolished the enhanced migration (39, 207).  
Additionally, LMP2A led to increased stability of the target transcription factor, c-Jun, and 
was shown to be hyperphosphorylated in LMP2A expressing cells (39).  Notably, an earlier 
study revealed that ERK could interact with and phosphorylate LMP2A at serine 15 and 
serine 102 in vitro (253).  One recent study showed that LMP2A can inhibit transforming 
growth factor-β1 (TGF-β1) in gastric carcinoma cells as well as in an EBV-negative B cell 
line (98).  The study showed that LMP2A could partially block apoptosis triggered by 
treatment with TGF-β1 via PI3K/Akt pathway activation.  The diverse signaling capabilities 
of LMP2A in both B lymphocytes and epithelial cells highlight its importance in EBV 
latency as well as EBV-associated diseases. 
 
EBV-Associated Diseases 
 Fortunately, the infection and lifetime persistence of EBV is typically asymptomatic.  
However, viral infection can result in disease.  Host factors such as age, genetic background, 
immune status, and behaviors can affect the development of EBV-associated diseases.  
Notably, EBV-associated disease varies in severity from self-limited episodes to fatal 
outcomes. 
 
Infectious Mononucleosis  
 Although primary infection with EBV is usually asymptomatic, delay of primary 
infection until adolescence or early adulthood can result in infectious mononucleosis (IM).  
Symptoms of IM include fever, pharyngitis, lymphadenopathy, hepatomegaly, splenomegaly, 
and malaise (46, 72, 275).  Occasionally, complications including splenic rupture, anemia, 
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and hepatitis arise (46).  The symptoms associated with IM are generally due to the massive 
response of the immune system to infection of the B cell compartment.  IM results in an 
increase of pro-inflammatory cytokines such as IL-1, IFN-γ, and TNF-α released by T 
lymphocytes in response to lytic and latent viral antigens (2, 243).  The CD8 positive T-cell 
memory response is maintained for the lifetime of the host and typically constitutes up to 5% 
of the total circulating CD8 positive T-cell population (132). During IM, individuals shed 
high titers of virus in the saliva from lytic infection in the oropharynx in addition to 
maintaining large numbers of latently infected, EBNA2 and LMP1 positive, lymphoblasts in 
the tonsillar lymph nodes (7, 182).  The disease generally resolves itself over the course of 
weeks to months, and an asymptomatic, latent carrier state in the host is established. 
 
Oral Hairy Leukoplakia 
 Oral Hairy Leukoplakia (OHL) typically develops when an EBV-infected individual 
become immunocomprimised, as in the case of acquired immune deficiency syndrome 
(AIDS).  OHL appears as a raised, white, corrugated lesion on the oral epithelium, typically 
on the lateral borders of the tongue (109) .  It is a focus of EBV lytic infection, with viral 
lytic proteins and linear EBV genomes present (103, 252) .  Additionally, some latent viral 
proteins such as EBNA1, EBNA2 and LMP1 can also be detected (339).  Typically, OHL 
lesions respond well to treatment with acyclovir, a nucleoside analog that inhibits the viral 
DNA polymerase (274). 
 
 
 
 21 
X-linked Lymphoproliferative Syndrome 
 X-linked lymphoproliferative syndrome (XLPS) is a disease in males who inherit a 
mutation in the gene encoding the signaling lymphocyte activation molecule (SLAM)-
associated protein (235, 236, 300).  These individuals have impaired interactions between B 
and T cells, thereby making them extraordinarily sensitive to EBV infection (13, 266).  Upon 
primary EBV infection, their immune systems are unable to control the proliferation of EBV-
infected B lymphocytes.  The majority of patients present with hyperacute IM followed by 
hepatic failure and subsequent death (275).  If the patient survives the episode of IM, they 
then may succumb to lymphoma or hypogammaglobulinemia (46, 275). 
 
Chronic Active EBV Infection 
 Typical IM infections generally result in the resolution of the infection with the host 
returning to an asymptomatic state.  In some instances, patients present with chronic fatigue, 
fever, and other symptoms for several years after primary EBV infection.  Diagnosis of 
chronic active EBV infection (CAEBV) is dependent on three criteria:  severe progressive 
illness that is associated with abnormally high EBV-specific antibody titers, major organ 
involvement, and detection of EBV proteins, RNA, or DNA in the affected tissues (3, 129, 
247, 294).  Although the exact cause of CAEBV is unknown, studies have speculated that the 
defective cytotoxic activity of NK cells and CTLs in conjunction with genetic factors may be 
responsible for or contribute to the development of CAEBV (95, 160, 166, 328). 
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Virus Associated Hemophagocytic Syndrome 
 Virus associated hemophagocytic syndrome (VAHS) is a T cell lymphoma primarily 
found in Southeast Asian populations.  VAHS can occur alone or in conjunction with IM, 
CAEBV, XLPS, or lymphoproliferative disease (9, 40, 43, 136, 150).  VAHS typically 
affects children and adolescents, and symptoms include persistent fever, liver dysfunction, 
cytopenia, hepatosplenomegaly, and hemophagocytosis in various tissues often resulting in 
death (148). 
 
EBV-Associated Malignancies 
 Although most EBV infected individuals remain asymptomatic for the course of their 
lives, a subset of people will develop an EBV-associated malignancy.  Both geographical 
location and immune status are linked to the risk of tumor development.  Since EBV 
infection is associated with B cells and epithelial cells, the common EBV-associated 
malignancies are of lymphoid and epithelial origin.  EBV-associated tumors are strongly 
linked to latent infection as the genomes located in them are episomal and clonal and viral 
gene expression falls into one of the three latency categories (268).  Notably, expression of 
lytic EBV proteins has been observed in some tumors and may partly contribute to 
tumorigenesis (137, 295). 
 
Burkitt’s Lymphoma 
 Burkitt’s lymphoma (BL) is divided into three categories:  endemic, sporadic, and 
AIDS-associated.  All EBV-associated BL has a Type I latency expression profile, with the 
viral products limited to EBNA1, the EBERs, and the BARTs (275). Endemic BL is the most 
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common form and is the leading childhood cancer in equatorial Africa and New Guinea with 
a high incidence and a marked geographic distribution that correlates with endemic malaria 
(24, 25, 27, 211, 262).  Notably, endemic BL tumors are always EBV positive (16).  Endemic 
BL typically develops at extranodal sites in the jaw during molar eruption (275).  Tumors are 
homogeneous, monoclonal, and composed of B lymphocytes that are similar to germinal 
center B lymphocytes (66, 268).  Both endemic and sporadic BL are characterized by a 
chromosomal translocation that places the c-myc oncogene under the control of the Ig heavy 
or light chain promoter, leading to its aberrant expression in B lymphocytes (51). 
 Sporadic BL does not have a specific geographical distribution and its association 
with EBV varies greatly.  The incidence of sporadic BL is much lower than endemic BL and 
the disease typically strikes at a later age.  Additionally, sporadic BL presents differently as it 
is usually associated with an abdominal mass and can appear as a leukemia (211). 
 In HIV infected individuals, a small B cell lymphoma similar to BL appears in the 
early stages of AIDS when the T cell population is largely unaffected.  This type of BL has a 
30-40% association with EBV.  This lymphoma type lacks EBNA2 and LMP1 expression 
and often heralds the onset of AIDS (34, 99, 117, 172). 
 
Hodgkin Lymphoma 
 In the United States, Hodgkin lymphoma (HL) is one of the most commonly 
occurring cancers in young adults.  Approximately 40% of HL cases in industrialized nations 
are EBV-positive and nearly 100% are EBV-positive in developing nations (141).  Incidence 
of HL peaks in early adulthood, typically in the 30s and then peaks again in older adults.  
Additionally, males are more affected by HL than women, particularly as age increases 
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(156).  Persons with a history of IM have a three-to-four-fold risk of developing HL (106).  
Notably, HL in patients with a history of IM is less likely to be EBV-associated.  HL is 
divided into several subtypes that vary with EBV status, histology, incidence, and prognosis. 
 The malignant cells of HL, known at Hodgkin/Reed-Sternberg cells (HRS), arise 
from germinal center B cells, are clonal, and multinucleated with abundant cytoplasm (36, 
149).  HRS cells stain positive for EBV DNA and exhibit a Type II latency gene expression 
pattern with no chromosomal abnormalities (6, 18, 181, 343, 344).  HRS cells are associated 
with increased NFκB activity as well as increased levels of Bcl-2, p53, and IL-10 (263).  
Notably, a study has shown that LMP2A expression in the B cells of transgenic mice leads to 
a myriad of changes in B cell transcription similar to the transcription patterns seen in HL 
HRS cells (264). 
 
Post-Transplant Lymphoproliferative Disorders 
 Chronic, pharmacologic-induced immunosuppression in transplant patients allows for 
uncontrolled proliferation of EBV-infected B lymphocytes and can lead to the development 
of post-transplant lymphoproliferative disorder (PTLD).  PTLD occurs with variable 
incidence in renal, liver, heart, lung and bone marrow transplants (275).  Since bone marrow 
transplants typically require the total elimination of host lymphoid cells, PTLD likely stems 
from EBV-infected donor B lymphocytes in the transplanted marrow (108, 115).  
Furthermore, patients who are EBV negative before transplantation have a greater risk of 
developing PTLD (134).  Both the reduction of immunosuppressive therapy and the 
depletion of graft B- and T-lymphocytes can reduce the incidence of PTLD (115, 303). 
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 PTLD typically occurs within two years post transplantation.  Approximately 90% of 
lesions are associated with EBV and exhibit a Type III latency expression pattern with 
EBNA1, EBNA2, and LMP1 found in the majority of EBV-associated lesions (195, 318, 
352).  In some instances, p53 and c-myc mutations are associated with PTLD (195, 318, 352).  
Of note, EBNA2 is not always detected in AIDS-associated PTLD, suggesting a Type II 
latency gene expression pattern (58, 177, 221). 
 
Nasopharyngeal Carcinoma 
 Undifferentiated nasopharyngeal carcinoma (NPC) is intimately associated with EBV 
and is a result of EBV infection of the epithelium (267).  In all cases, this undifferentiated 
form of NPC consists of monoclonal EBV-infected epithelial cells of nasopharyngeal origin 
and exhibits a Type II latency gene expression pattern (22, 38, 74, 268, 269, 347, 353).  
Although uncommon in the United States and Europe, NPC is endemic to parts of Southeast 
Asia and Northern Africa (356).  The incidence of NPC is related to cultural and 
environmental factors such as salted fish consumption and exposure to chemical carcinogens, 
as well as genetic factors such as HLA type (267, 275, 356). 
 NPC is comprised of malignant epithelial cells surrounded and infiltrated by 
lymphocytes and granulocytes (267).  NPC is a highly invasive and metastatic tumor, and 
over 50% of patients have metastases at the time of diagnosis.  Loss of the p16 tumor 
suppressor has been linked to NPC development and progression by allowing cells to bypass 
a critical cell cycle checkpoint (201).  One study detected specific activation of NFκB p50 
homodimers by LMP1 in NPC, indicating this pathway may be involved in pathogenesis 
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(322).  The activation of the NFκB pathway may be responsible for the upregulation of 
epidermal growth factor receptor (EGFR) seen in NPC (228, 229, 308).   
 HLA haplotype also contributes to NPC pathogenesis as genes closely related to HLA 
are associated with an increased risk for NPC development (64, 208).  HLA haplotypes 
HLA-A2, BW46, A19, B17 class I, and HLA-DR β10803 class II are associated with an 
increased risk for NPC, whereas HLA A11 and B13 class I have a decreased risk (64, 275).  
Although the majority of the high risk haplotypes are prevalent in China, Chinese immigrants 
and their children have a reduced risk for NPC, indicating the importance of environmental 
factors (64, 275). 
 Overall, the role of EBV in initiating NPC is poorly understood.  EBV cannot 
transform epithelial cells, but it is readily detectable in pre-malignant lesions of the 
nasopharynx, suggesting that is may play a part in the early stages of NPC development (258, 
345).  LMP2A is abundantly transcribed in NPC, and NPC patients have high titers of 
antibodies against LMP2A, suggesting it is also expressed at the protein level (22, 29, 189).  
In one report, LMP2A protein expression was detected by immunohistochemistry in 
approximately 46% of NPC tumors examined (130).  Futhermore, LMP2A has been shown 
to activate the PI3K/Akt signaling pathway in epithelial cells (237, 292).  Activation of this 
pathway could facilitate transformation and growth of EBV infected cells through the 
activation of cell survival and proliferation pathways. 
 
Gastric Carcinoma 
 Research has shown that approximately 10% of gastric carcinomas are comprised of 
monoclonal, EBV infected cells (145, 314).  EBV-associated gastric carcinoma deviates from 
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the standard latency type classifications.  They have a modified Type II latency expression 
pattern with the additional expression of the latent BARF1 gene in addition to several lytic 
genes such as BZLF1, BRLF1, and BLLF1 in some instances (137, 361).  Notably, expression 
of LMP1 and LMP2B is frequently absent in these tumors, which also deviates from classical 
Type II latency (307). 
 The lack of LMP1 expression in these tumors suggests a more critical role for 
LMP2A in gastric carcinogenesis.  LMP2A has previously been shown to have oncogenic 
properties in the HaCaT human epithelial cell line (292).  In addition to LMP2A, expression 
of the BARF1 gene has been detected in some gastric carcinomas (361).  BARF1 was first 
described as a lytic protein, however, some studies have described its expression in epithelial 
malignancies with a modified Type II latency expression pattern (57, 122, 221, 361).  
BARF1 is the secreted viral homolog to human colony stimulating factor 1 and has 
immortalizing effects in primary primate epithelial cells and transforming effects in human B 
lymphocytes and rodent fibroblasts (248, 297, 305, 319, 340-342).  Additionally, one study 
showed that the addition to BARF1 to serum starved cultures of rodent fibroblasts, primate 
epithelial cells, and human B cells resulted in cell cycle activation and progression (288).  
This potential role for BARF1 as a growth factor could contribute to the establishment and 
progression of EBV-associated gastric carcinomas. 
 
Other Associated Malignancies 
 In addition to the previously described malignancies, EBV has also been associated 
with several other malignancies.  T cell and NK cell lymphomas as well as some non-
Hodgkin B cell lymphomas are infected with EBV (55, 142, 163, 218, 249).  Additionally, 
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central nervous system lymphomas arising in HIV patients have a strong connection to EBV 
(210).  There have also been several reports of EBV-associated breast cancers, but these 
findings have been, and remain controversial (21, 44, 185).  Lastly, leiomyosarcoma, a rare 
smooth muscle tumor, is strongly associated with EBV in the context of immunosuppression 
(186, 217). 
 
Therapeutics 
 Drugs that induce the EBV lytic cycle in conjunction with the nucleoside analog 
gancyclovir as well as demethylating agents such as 5-azacytidine, have been used to directly 
target the EBV life cycle (5, 79, 152).  Chemical compounds targeting individual EBV 
proteins through RNA interference (RNAi), single-chain antibodies, or by inhibiting signal 
transduction pathways used by the virus, such as NFκB, have had minimal success (30, 78, 
170, 261).  A more effective approach involved the infusion of effector T cells prepared from 
the bone marrow donor by autologous LCL stimulation and expansion in vitro.  This method 
has been successful in bone marrow transplants and now a similar adoptive transfer approach 
is being used for PTLD cases and solid organ transplants (283, 355). 
 
Rhesus Lymphocryptovirus 
 Infection of Old World primates with EBV related lymphocryptoviruses (LCV) was 
first recognized in the early 1970s when investigators developed and immunoflourescence 
assay to detect antibodies cross-reactive to the EBV viral capsid antigen (VCA) in the serum 
of Old World primates (62, 162).  Subsequently, LCV infected cell lines were established 
from both healthy and diseased Old World primates.  Simian LCV infected cell lines 
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produced virus that could immortalize B cells from autologous and closely related species in 
vitro (77, 97, 100).  These cell lines also expressed latent infection nuclear antigens similar to 
EBV EBNAs, but these antigens did not cross react well with EBV immune human sera (61, 
101, 193, 246).  More recent work has shown that rhesus LCV can also infect epithelial cells 
in immunosuppressed macaques and induce epithelial lesions resembling oral hairy 
leukoplakia in AIDS patients (184). 
 In vivo, LCV infection in primates resembles EBV infection in humans.  Newborn 
animals are sero-positive for VCA antibodies due to maternal antibody transfer. They 
become sero-negative within four to six months after birth, and then most sero convert again 
within a year, indicating a high prevalence of infection (87, 96, 157).  Lifelong antibody 
responses, the ability to recover LCV infected B cell lines from the peripheral blood of 
healthy animals, and the ability to detect virus shed from the oropharynx indicate that a 
similar host-LCV relationship exists in primates as with EBV and humans (231). 
 Studies into the LCV genome revealed a similar DNA organization to EBV (123, 
124).  Notably, EBV DNA cross-reacts with viral DNA from simian LCVs with the 
exception of the EBNA3s, LMP1, and LMP2 (123, 124).  Rhesus LCV homologs for most of 
the EBV latent genes have been described (42).  In virtually all aspects, these rhesus LCV 
latent genes are functionally interchangeable with the EBV genes despite varying degrees of 
homology. 
 The rhesus LCV homolog for EBV LMP2A was readily identified by the 
conservation of the characteristic ITAM motif (88, 276).  The full-length rhesus LCV 
LMP2A was deduced from the genomic sequence and confirmed by RT-PCR analysis.  The 
12 transmembranes are well conserved, and the cytoplasmic domain associated with 
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signaling is somewhat divergent.  Despite this sequence divergence, the ITAM and praline 
rich domains that are important for interaction with protein tyrosine kinases (PTKs) are 
conserved and the rhesus LCV LMP2A both induces PTKs and are themselves tyrosine 
phosphorylated.  It remains unclear whether rhesus LCV LMP2A is dispensable for B cell 
transformation as in the case of EBV.  However, it is clear that there is strong selective 
pressure for LMP2A as it is evolutionarily conserved (276). 
 
Matrix Metalloproteinases 
 There are currently 24 members of the matrix metalloproteinase (MMP) family which 
all share a catalytic domain coordinated by zinc, which catalyze the degradation of protein 
components of the extracellular matrix (ECM) in their own environment, as well as 
activating latent growth factors, cell surface receptors, and adhesion molecules (35, 250).  
Cell-ECM interactions trigger cellular signaling that promotes cell differentiation, migration, 
and mobilization, essential for homeostasis.  Accordingly, the balanced and regulated 
degradation of ECM proteins by MMPs is involved in numerous physiological processes 
including wound healing, tissue remodeling, angiogenesis, and embryo development (304).  
Conversely, excess MMP activity plays a role in several diseases including rheumatoid 
arthritis, osteoarthritis, autoimmune diseases, cardiovascular diseases, and cancer. MMPs 
have been regarded as critical molecules assisting tumor cells during metastasis (65, 304).  
From the earliest work on MMPs in cancer, there has been a clear connection between 
MMPs, ECM degradation, and cancer cell invasion.  Numerous studies have linked inhibition 
of MMPs with a corresponding inhibition of cell invasion.  Conversely, upregulation of 
MMPs usually leads to enhanced tumor cell invasion (59, 196, 197). 
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 With regards to EBV, work has shown that MMP-9 is induced by LMP1 expression 
in C33A human epithelial cells (316).  This report indicated that MMP-9 expression and 
activity were dependent on LMP1 mediated activation of the NFκB pathway.  These results 
indicate that LMP1 may contribute to NPC invasiveness and metastasis. 
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OBJECTIVES 
 EBV LMP2A is a latent protein that is expressed in most EBV-associated 
malignancies.  This broad spectrum of expression indicates important roles for LMP2A in 
oncogenesis.  As previously noted, the importance of LMP2A in B lymphocytes has been 
well established, but its role in epithelial cells is only beginning to unfold.  The goal of these 
studies is to evaluate the properties EBV LMP2A and rhesus LMP2A in epithelial cells and 
how these properties can contribute to EBV pathogenesis. 
 
Aim 1.  Characterization of rhesus LMP2A expression in epithelial cells 
 Previous work in our lab has shown that LMP2A activates PI3K/Akt signaling in 
HFK cells and this signaling pathway was responsible for the translocation of β-catenin to the 
nucleus.  In this study, we assess the activation of this pathway by the rhesus LMP2A 
homolog in HFK cells to determine if it behaves in a similar fashion to EBV LMP2A. 
Aim 2.  Microarray analysis of EBV LMP2A expressing HFK cells 
 The goal of this aim is to identify and assess LMP2A targets that may affect cell 
migration and adhesion.  Here we identify MMP proteins and identify the signaling pathways 
involved in their LMP2A mediated expression and activity. 
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ABSTRACT 
 
Rhesus lymphocryptovirus (LCV) is a γ-herpesvirus closely related to Epstein-Barr virus 
(EBV).  The rhesus latent membrane protein 2A (LMP2A) is highly homologous to EBV 
LMP2A.  EBV LMP2A activates the phosphatidylinositol 3-kinase (PI3K) and β-catenin 
signaling pathways in epithelial cells and affects differentiation.  In the present study, the 
biochemical and biological properties of rhesus LMP2A in epithelial cells were investigated.  
The expression of rhesus LMP2A in epithelial cells induced Akt activation, GSK3β 
inactivation and accumulation of β-catenin in the cytoplasm and nucleus.  The nuclear 
translocation, but not accumulation of β-catenin was dependent on Akt activation.  Rhesus 
LMP2A also impaired epithelial cell differentiation; however, this process was not dependent 
upon Akt activation.  A mutant rhesus LMP2A lacking six transmembrane domains 
functioned similarly to wild-type rhesus LMP2A indicating that the full number of 
transmembrane domains is not required for effects on β-catenin or cell differentiation.  These 
results underscore the similarity of LCV to EBV and the suitability of the macaque as an 
animal model for studying EBV pathogenesis. 
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INTRODUCTION  
Epstein-Barr virus (EBV) is a γ-herpesvirus within the lymphocryptovirus (LCV) 
subgroup.  EBV is the etiologic agent of infectious mononucleosis and it is closely associated 
with numerous diseases including nasopharyngeal carcinoma, Burkitt’s lymphoma, 
Hodgkin’s disease, and numerous lymphoproliferative disorders, particularly in 
immunocompromised individuals (20).  The majority of Old World primates are naturally 
infected with simian homologs of EBV.  As with EBV infection in humans, infection is 
ubiquitous in animals raised both in captivity and in the wild. These simian homologs share 
many genetic, biologic, pathogenic, and epidemiologic properties with human EBV.  Rhesus 
EBV (cercopithicine herpesvirus 15) can immortalize B cells in vitro (14) and has an 
identical genetic repertoire to EBV with an overall sequence homology of 75% (21).  Rhesus 
EBV can also induce B-cell tumors in animals immunosuppressed due to simian 
immunodeficiency virus infection similar to the development of EBV induced tumors in 
AIDS patients (6, 7).  Recently, rhesus EBV has been shown to infect epithelial cells in 
immunosuppressed macaques and can induce epithelial cell lesions that resemble oral hairy 
leukoplakia in AIDS patients (11).  Additionally, a previous study has shown that rhesus 
macaques experimentally infected with rhesus EBV exhibited acute and persistent infections 
similar to EBV infection in humans, thus indicating that rhesus macaques are a suitable 
animal model for EBV (15). 
These striking similarities between rhesus LCV and EBV and the 62% amino acid 
similarity suggest that the molecular properties of rhesus LMP2A (Rh-L2A) would be 
similar.  EBV LMP2A has previously been shown to have striking properties in epithelial 
cells where its expression in human keratinocyte cell line, HaCaT, induced PI3K activation 
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and the subsequent phosphorylation and activation of Akt (22).  In addition, HaCaT cells 
expressing EBV LMP2A had impaired differentiation when grown in organotypic raft 
cultures.  In human telomerase immortalized human foreskin keratinocytes, HFK cells, 
LMP2A expression activated both the PI3K/Akt signaling and Wnt/β-catenin signaling 
pathways.  The activation of these pathways led to the subsequent phosphorylation and 
inactivation of the Akt target GSK3β.  The effects on these pathways also increased the 
levels and induced the nuclear translocation of β-catenin resulting in activation of TCF 
mediated transcription (17).  In HFK cells, EBV LMP2A also inhibited epithelial cell 
differentiation in assays where differentiation was induced by suspension in methylcellulose.  
In these assays, involucrin and keratinocyte transglutaminase increase during differentiation 
and these increases were blocked by EBV LMP2A (18). 
In this study, the effects of Rh-L2A expression were analyzed in the HFK epithelial 
cells.  Additionally, a mutant Rh-L2A (Rh-L2A∆C ) lacking the C-terminal six 
transmembrane domains was examined.  The N-terminus of EBV LMP2A contains multiple 
important signaling motifs including a src binding site, an ITAM motif, and a PY motif that 
is essential for interactions with Nedd4 ubiquitin ligases.  These motifs are retained in Rh-
L2A and in Rh-L2A∆C.   The data presented here indicate that both Rh-L2A and the 
truncation mutant induced the phosphorylation and activation of Akt and the phosphorylation 
of an Akt target, GSK3β.  Rh-L2A∆C increased cytoplasmic and nuclear levels of β-catenin 
and the translocation of β-catenin was blocked by treatment with the Akt inhibitor, 
triciribine.  In a novel differentiation assay, Rh-L2A expressing cells had decreased levels of 
both involucrin.  Interestingly, loss of six transmembrane domains did not impair the 
properties of Rh-L2A∆C.   In addition, inhibition of Akt did not affect the ability of LMP2A 
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to block differentiation.  These data indicate that the rhesus homolog of EBV LMP2A 
behaves in a similar manner to EBV LMP2A in epithelial cells and further validates the 
rhesus macaque as an animal model for the study of EBV infection and pathogenesis in 
epithelial cells. 
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MATERIALS AND METHODS 
 
Cell culture and retrovirus.  Human foreskin keratinocytes (HFK) immortalized 
with human telomerase (5) were cultured in serum-free keratinocyte media (K-SFM, Gibco) 
supplemented with 2ng/ml of epidermal growth factor, 30µg/ml bovine pituitary extract, and 
1% antibiotic-antimycotic solution (Gibco).  293T cells were maintained in Dulbecco’s 
modified Eagle medium (DMEM, Gibco) supplemented with 10% FBS and 1% antibiotic-
antimycotic solution.  Both HFK and 293T cells were grown at 37°C in a humidified 
incubator with 5% CO2.  To create stable cell lines, recombinant retroviruses expressing 
either vector alone (pBabe) or vector subcloned with FLAG-tagged rhesus LMP2A (pBabe-
Rh-L2A) were generated as previously described using FuGene 6 transfection reagent 
(Roche) according to manufacturer’s instructions and used to transduce HFK cells (22).  
Pools of stable cells expressing either pBabe, pBabe-Rh-L2A, and pBabe-Rh-L2A∆C were 
selected for in the presence of .5µg/ml puromycin (Sigma). 
 
Lysate preparation and cellular fractionations.  Whole cell lysates were prepared 
using Nonidet P-40 (NP-40) lysis buffer containing 50mM Tris-HCl, 150mM NaCl, 2mM 
EDTA, 10% glycerol, 1% NP-40, 1mM sodium vanadate (Na3VO4), 0.4mM 
phenylmethylsulfonyl fluoride (PMSF), and protease and phosphatase cocktails (Sigma) at 
1:100.  Cellular fractionations were performed using OptiPrep (Sigma) according to a 
modified manufacturer’s protocol.  In brief, cells were resuspended in buffer A (20mM 
HEPES, 10mM KCl, 0.1mM EDTA, 0.1mM EGTA, 1mM dithiothreitol, 1mM Na3VO4, 
0.5mM PMSF, and protease and phosphatase inhibitor cocktails at 1:100) with 1% NP-40.  
 72 
Crude nuclei were pelleted at 1000 rpm and cytosolic fractions extracted.  Nuclei were 
purified over an OptiPrep gradient with 25, 30, and 35% layers and then lysed with a 
hypotonic buffer (20mM Tris-HCl, 400mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 25% 
glycerol, 1mM Na3VO4, 0.5mM PMSF, and protease and phosphatase inhibitor cocktails at 
1:100). 
 
Differentiation assays.  To set up the assay, approximately 4x106 HFK cells 
expressing Rh-L2A, Rh-L2A∆C, or vector alone were plated in 100mm Petri dishes 
containing keratinocyte media and placed at 37°C overnight.  The keratinocyte media was 
then removed and replaced with DMEM and placed again at 37°C for 48h.  After the 
incubation period, cells were harvested and cell pellets were then lysed using Nonidet P-40 
(NP-40) lysis buffer containing 50mM Tris-HCl, 150mM NaCl, 2mM EDTA, 10% glycerol, 
1% NP-40, 1mM sodium vanadate (Na3VO4), 0.4mM phenylmethylsulfonyl fluoride 
(PMSF), and protease and phosphatase cocktails (Sigma) at 1:100. 
 
 Inhibitor experiments.  For fractionation and zero time experiments (cells not 
induced to differentiate), HFK cells were plated in either 100mm or 150mm dishes 
containing keratinocyte media.  Within 24h post-seed, triciribine (TCN) was added to the 
media at a concentration of 5µM.  Control plates were treated with an equivalent volume of 
DMSO (vehicle control).  After 24h of inhibitor treatment, cells were harvested and lysates 
generated for Western blot analysis.  For differentiation experiments, HFK cells were plated 
in 100mm Petri dishes containing standard DMEM media to induce differentiation.  At 24h 
post-seed, TCN was added to the media at a concentration of 5µM.  DMSO was used as a 
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vehicle control.  At 24h post-treatment (48h into the induction of differentiation), cells were 
harvested and lysates generated for Western blot analysis. 
 
Western blot analysis and antibodies.  Protein concentrations were determined 
using the Bio-Rad DC assay system according to manufacturer’s instructions.  Lysates were 
boiled in a protein loading solution containing SDS and β-mercaptoethanol for five minutes 
and subjected to SDS-10% polyacrylamide gel electrophoresis.  Proteins were transferred to 
an Optitran nitrocellulose membrane (Schleicher & Schuell) and subjected to Western blot 
analysis.  Antibodies used include anti-involucrin antibody from Sigma; anti-Akt, anti-
phospho-Akt Ser473 and anti-phospho-GSK3β from Cell Signaling; anti-actin from Santa 
Cruz; and anti-β-catenin from Transduction Laboratories.  Horseradish peroxidase secondary 
antibodies (Amersham) and SuperSignal West Pico System (Pierce) were used to detect 
antibody bound proteins. 
 
Immunoflourescence.  HFK cells expressing pBabe, Rh-L2A, or Rh-L2A∆C were 
plated in six well plates containing a coverslip.  Approximately 24h post seed, the cells were 
fixed with 4% paraformaldehyde for 15 minutes at RT.  Cells were then washed 3X with 
PBS and anti-FLAG antibody (Sigma) or DAPI (Molecular Probes) was applied as specified 
by the manufacturer.  Again, cells were washed 3X with PBS and a FITC-conjugated anti-
mouse secondary antibody (Jackson ImmunoResearch) was added according to 
manufacturer’s instructions.  Cells were then washed 3X with PBS and mounted on 
coverslips using an anti-fade mounting medium.  
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RESULTS 
Rhesus LMP2A signaling in telomerase immortalized HFK cells activates the PI3K/Akt 
pathway.  EBV LMP2A has been shown to activate Akt via the PI3K pathway in both 
lymphocytes and epithelial cells (17, 22, 24).  To investigate whether rhesus LMP2A (Rh-
L2A) and the C-terminus deletion mutant, Rh-L2A∆C, also activate Akt in epithelial cells, 
RhL2A was expressed in HFK cells.  Stable HFK cell lines expressing FLAG-tagged Rh-
L2A or Rh-L2A∆C in the pBabe vector or vector alone were developed, and pools of stably 
expressing cells generated after puromycin selection.  Immunoflourescent 
immunohistochemistry and immunoblotting with anti-FLAG antiabody confirmed the 
expression of FLAG-tagged Rh-L2A and Rh-L2A∆C in the stable cell lines (Fig.1). 
Immunohistochemistry staining indicated expression in all cells.  DAPI staining of the 
nucleus and overlay with the FLAG antibody revealed that the majority of the protein was 
located at the perinuclear membrane.  Despite the loss of six transmembrane domains, the 
Rh-L2A∆C mutant also localized to the perinuclear membrane (Fig. 1A).  Expression of the 
two forms was also identified by immunoblotting with anti-FLAG antibody (Fig.1B).  The 
full-length Rh-L2A migrated with a MW of 55 kDa, while the Rh-L2A∆C had the 
appropriate MW of 42 kDa. 
 To detect activated Akt, Western blot analysis was performed using a 
phosphospecific antibody directed against Ser473 to detect activated Akt (Fig. 2A).  Both 
Rh-L2A and Rh-L2A∆C activated Akt to levels higher than the pBabe control. These data 
indicated the similarity with EBV LMP2A in that both Rh-L2A and Rh-L2A∆C activated 
Akt in HFK cells and that the C-terminus of Rh-L2A was not required for this function. 
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Figure 1: Expression of Rh-L2A in human foreskin keratinocytes.  HFK cells were 
transduced with the pBabe (vector) retrovirus alone or expressing Rh-L2A.  Transduced cells 
were placed under puromycin selection.  A)  Expression was determined by 
immunoflourescence using an anti-FLAG antibody.  DAPI was used to visualize the nuclei.  
B) Immunoblot was prepared with equal amounts of protein of the Rh-L2A and Rh-L2A∆C 
expressing HFK cells and reacted with anti-FLAG antibody.
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Figure 2:  Rh-L2A and Rh-L2A∆C phosphorylate and activate Akt in HFK cells.  Cells lines 
expressing Rh-L2A, Rh-L2A∆C, or vector alone were harvested, lysed, and subjected to 
Western blot analysis.  To detect the activated form of Akt, a phospho specific antibody for 
Ser473 was used.  Total Akt was used for a loading control and densitometry with Image J 
software was performed to normalize p-Akt levels to the corresponding total Akt levels.  
Fold increase of the normalized p-Akt values are depicted in panel B. The Fig. shown is a 
representative experiment from five independent experiments. 
 
 
Akt can phosphorylate and affect the activity of many proteins including glycogen synthase 
kinase beta (GSK3β) (2).  GSK3β is an important enzyme involved in regulating glycogen 
storage and wnt signaling.  Phosphorylation by Akt at Ser9 inactivates GSK3β, suggesting 
that Akt is involved in controlling cellular metabolism.  This inactivation may affect cellular 
metabolism, survival and/or cell cycle progression.  Western blot analysis with phospho-
specific antibodies revealed increased phosphorylation of GSK3β in both Rh-L2A and Rh-
L2A∆C expressing cells relative to vector control cells (Fig. 3).  These data indicate that Rh-
L2A expression in HFK cells leads to the activation of Akt and subsequent phosphorylation 
and inactivation of the Akt target GSK3β and that the C-terminus of Rh-L2A is not necessary 
for this function.  Interestingly, endogenous levels of β-catenin were increased in the Rh-L2A 
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expressing cells and levels of involucrin, a terminal differentiation marker, were reduced 
(Fig. 3).  These data further indicated the similarity in the function of Rh-L2A with EBV 
LMP2A (17). 
 
Figure 3:  Rh-L2A and Rh-L2A∆C reduce involucrin levels and increase levels of β-catenin 
and p-GSK3β in HFK cells.  HFK cells stably expressing Rh-L2A, Rh-L2A∆C, or vector 
alone were harvested, lysed and subjected to Western blot analysis.  A phospho-specific 
antibody directed against Ser9 was utilized to detect the inactivated form of GSK3β.  Actin 
served as a loading control.  Panel B is a graphical depiction of the quantitation performed on 
the blot shown in part A and is representative of four independent experiments.  Quantitation 
analysis was performed using ImageJ software. 
 
 
Rh-L2A signaling results in increased expression and nuclear accumulation of β-catenin 
in HFK cells.  GSK3β can bind to the axin complex and within this complex GSK3β 
phosphorylates β-catenin thereby targeting it for ubiquitination and degradation via the 
proteosome (19).  Phosphorylation of GSK3β by Akt blocks GSK3β kinase activity, however 
this GSK3β inactivation does not always affect β-catenin accumulation and localization (3).  
For example, in 293 cells and CHO cells expressing insulin receptor, GSK3β inactivation due 
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to insulin signaling did not induce β-catenin accumulation and activation of TCF/LEF 
transcription factors.  However, Wnt signaling activation did induce β–catenin accumulation 
and transcriptional activation without inducing the phosphorylation of GSK3β (4).  Previous 
work from our laboratory has shown a PI3K activation requirement for the nuclear 
translocation of β-catenin in HFK cells expressing EBV LMP2A (17).  To investigate the 
effects of Rh-L2A and Rh-L2A∆C on the β-catenin/Wnt pathway and the status of 
endogenous β-catenin, a fractionation experiment was performed with Rh-L2A and Rh-
L2A∆C expressing HFK cells.  Stable cell lines expressing Rh-L2A, Rh-L2A∆C or vector 
alone were fractionated and levels of β-catenin were determined by immunoblotting of 
nuclear and cytosolic extracts with an antibody directed against β-catenin (Fig. 4).  HFK cells 
express abundant levels of β-catenin such that expression of Rh-L2A or Rh-L2A∆C had a 
minimal effect on the cytosolic amounts of β-catenin compared with vector alone.  However, 
nuclear β-catenin levels were considerably increased in the HFK cells expressing Rh-L2A 
and Rh-L2A∆C over cells expressing vector alone (Fig. 4).  These results indicated that Rh-
L2A and Rh-L2A∆C induce the nuclear translocation of β-catenin similarly to that observed 
in EBV LMP2A expressing cells. 
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Figure 4:  Rh-L2A and Rh-L2A∆C increases levels of nuclear β-catenin in HFK cells.  Cells 
stably expressing Rh-L2A, Rh-L2A∆C, or vector alone were harvested and fractionated into 
cytosolic and nuclear components.  Each component was subjected to Western blot analysis 
with antibodies to β-catenin, actin as a loading control, and GRP78 to attest to the purity of 
the fractions (data not shown).  Densitometry was performed with Image J software as 
previously described.  The fold increase of the normalized β-catenin values are graphically 
depicted in panel B and this is representative of three independent experiments. 
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Inhibition of Akt reduces expression and nuclear accumulation of β-catenin in Rh-L2A 
expressing cells.   Previous studies of EBV LMP2A indicated that accumulation of nuclear 
β-catenin was inhibited by the PI3K inhibitor, LY294002, however, the specific requirement 
for Akt activation was not determined.  To further delineate a specific requirement for 
activated Akt in this process and assess the contribution of the intact transmembrane 
domains, the effects of the Akt inhibitor, triciribine (TCN) were determined.  A previous 
study has shown that TCN is a potent and selective inhibitor of Akt in tumor cells (25).  TCN 
inhibits Akt by inducing a conformational change in the molecule that prevents it from 
becoming phosphorylated and phosphorylating its targets.  To determine the efficacy of TCN 
in our stable cell lines, cells expressing Rh-L2A, Rh-L2A∆C or vector alone were treated 
with a 5µM concentration of TCN or DMSO as a vehicle control.  Triciribine treatment 
effectively reduced the levels of phosphorylated Akt and GSK3β in all cells confirming 
previous work indicating that triciribine is an effective inhibitor of Akt activation (Fig. 5) 
(25).  Triciribine treatment did not affect the total β-catenin levels in Rh-L2A or Rh-L2A∆C 
expressing cells as compared to the vehicle control (Fig. 5).  These data confirm previous 
studies that indicated the inhibition of PI3K did not significantly affect the accumulation of 
cytosolic β-catenin (17). 
 Studies from our laboratory have also shown a requirement for PI3K signaling for 
inducing the nuclear translocation of β-catenin by EBV LMP2A (17).  To further investigate 
a specific role for Akt activation in this process and the contribution of the intact 
transmembrane domain, stable HFK cells expressing Rh-L2A∆C or vector alone were treated 
with TCN or DMSO as a vehicle control for 24h.  The cells were harvested, fractionated, and 
subjected to Western blot analysis.  Treatment with TCN considerably decreased the nuclear 
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Figure 5: Triciribine inhibits Akt activation in HFK cells.  Stable cell lines expressing Rh-
L2A, Rh-L2A∆C, or vector alone were treated with 5µM triciribine (TCN) for 24h prior to 
harvest.  Western blot analysis was performed using antibodies to β-catenin, Akt 
phosphorylated at Ser473, and GSK3β phosphorylated at Ser9. 
 
β-catenin in the Rh-L2A∆C cells and slightly decreased the levels in the vector control (Fig. 
6).  Similarly, treatment of cells expressing the full length Rh-L2A with triciribine also 
inhibited nuclear accumulation of β-catenin (data not shown).  These results indicated that 
the deletion of six transmembrane domains in Rh-L2A∆C did not affect this property of Rh-
L2A as both full length and Rh-L2A∆C induced nuclear translocation of β-catenin and this 
process specifically required activation of Akt.  
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Figure 6: Triciribine inhibits induction of nuclear β-catenin levels in HFK cells. Cells stably 
expressing Rh-L2A∆C or vector alone were harvested and fractionated into cytosolic and 
nuclear components 24h post triciribine treatment.  Each component was subjected to 
Western blot analysis with antibodies to β-catenin, actin as a loading control, and GRP78 to 
attest to the purity of the fractions (data not shown).  Densitometry was performed with 
Image J software as previously described.  The fold increase of the normalized β-catenin 
values are graphically depicted in panel B and this is representative of three independent 
experiments. 
 
 
Rh-L2A inhibits differentiation in HFK cells.  Previous studies have shown that EBV 
LMP2A blocks activation of B cells through the B-cell receptor and also can inhibit epithelial 
cell differentiation that is induced when HaCaT cells are grown in organotypic raft cultures 
(22).  Differentiation of HFK cells induced by growth in methylcellulose was also blocked as 
evidenced decreased involucrin (18).  To test other methods of inducing differentiation, cells 
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were plated in Petri dishes containing DMEM media instead of regular keratinocyte media.  
This has been shown to induce differentiation by impairing cell attachment and increasing 
calcium levels in a similar fashion to previously described methods (1). To further 
characterize the effects of Rh-L2A and Rh-L2A∆C expression on differentiation and to 
determine the efficacy of this method for the induction of differentiation, HFK cells 
expressing Rh-L2A, Rh-L2A∆C or vector alone were grown in Petri dishes with standard 
DMEM media to induce differentiation and subsequently analyzed for involucrin expression.  
During growth in regular keratinocyte media, the Rh-L2A and Rh-L2A∆C expressing cells 
had decreased levels of involucrin as compared to the control cells (Fig. 7A).  Upon the 
induction of differentiation, involucrin expression increased approximately 3 fold in the 
control cells.  In comparison, involucrin levels were remained considerably lower in both Rh-
L2A and Rh-L2A∆C expressing cells with an increase in involucrin of approximately 40% 
(Fig. 7B).  These data indicate that Rh-L2A expression negatively regulates differentiation in 
HFK cells in a similar manner to EBV LMP2A.  Furthermore, these data confirm that the C-
terminus of Rh-L2A is not required for LMP2A mediated inhibition of differentiation.  
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Figure 7: Rh-L2A inhibits differentiation in HFK cells.  Stable cells expressing Rh-L2A, Rh-
L2A∆C, or vector alone were plated in petri dishes containing standard DMEM media.  48h 
post seed, cells were harvested and lysates analyzed by Western blot.  The induction of 
differentiation was ascertained using an antibody directed against involucrin, a marker of 
terminal differentiation.  Actin was used as a loading control.  Panel B shows the fold 
increase of involucrin after differentiation normalized to actin and vector control cells at zero 
time.   Involucrin levels were determined by Image J software and are representative of five 
independent experiments. 
 
As inhibition of Akt effectively blocked the nuclear translocation of β-catenin, it was 
of interest to assess the contribution of Akt activation to the effects of LMP2A on markers of 
differentiation.  Interestingly, in cells that have not been induced to differentiate, treatment 
with triciribine did not affect the ability of Rh-L2A or Rh-L2A∆C to inhibit expression of the 
differentiation marker, involucrin.  Triciribine reduced levels of involucrin in both control 
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and Rh-L2A cells (Fig. 8).  These data suggest that the effects of Rh-L2A and Rh-L2A∆C on 
differentiation markers do not require activation of Akt. 
 
Figure 8:  Rh-L2A inhibition of involucrin expression is not Akt dependent.  HFK cells 
stably expressing Rh-L2A or vector alone were untreated or treated with triciribine (TCN) 
for 24h.  Cell lysates were analyzed by Western blotting. 
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DISCUSSION 
 This study reveals that the rhesus homolog of the EBV LMP2A protein has similar 
properties and can affect both the PI3K/Akt and Wnt/β–catenin signaling pathways in 
telomerase immortalized HFK cells.  Expression of both Rh-L2A and Rh-L2A∆C in HFK 
cells induced the phosphorylation and activation of Akt and subsequent phosphorylation and 
inactivation of the Akt target, GSK3β.  With the inactivation of GSK3β, β-catenin 
accumulated in the cytoplasm and translocated into the nucleus.  The nuclear translocation of 
β-catenin was dependent on Akt activation and the inhibition of Akt by triciribine blocked 
this effect (Fig. 6).  Previous work in our laboratory had shown a requirement for PI3K 
activation for the nuclear translocation of β-catenin, but not for cytosolic accumulation (17).   
The data presented here reveal that the requirement for PI3K is likely mediated by its effects 
on Akt.   
The present study also indicates that Rh-L2A blocks epithelial cell differentiation.  
Previous work from our laboratory has shown a similar role for EBV LMP2A in both HFK 
and HaCaT cell lines (17, 22).  Importantly, the data presented here clearly indicate that the 
loss of six of the twelve transmembrane domains does not affect the ability of Rh-L2A to 
activate the PI3K/Akt pathway or inhibit epithelial cell differentiation.  This likely reflects 
the retention of the signaling motifs within the cytoplasmic N-terminus of both proteins.  The 
N-terminus of both Rh-L2A and EBV LMP2A contain PY and ITAM motifs which are 
involved in many functions of the protein.  The two proline rich PY motifs are known to 
interact with members of the Nedd4 family of ubiquitin ligases such as AIP4 and Itch in B 
cells (10).  Through the ITAM motif the PI3K/Akt pathway is activated and associates with 
Syk kinase in B cells (8, 24).  Additionally, the ITAM and PY motifs are involved in 
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PI3K/Akt and β-catenin signaling in epithelial cells (17, 23).  The data presented here 
confirm that these properties of LMP2A require the motifs at the N-terminus but do not 
require the full complement of transmembrane domains.  The transmembrane domains are 
thought to contribute to oligomerization and constitutive signaling.  Previously, the 
contribution of the LMP2 transmembrane domains to B-lymphocytes immortalization was 
assessed using genetically engineered EBV.  Deletion of the last seven transmembrane or 
first five transmembrane spanning domains did not impair B-cell immortalization by EBV 
(12, 13).  The data presented here indicate that six transmembrane domains are also sufficient 
for the effects of Rh-L2A in epithelial cells.    
 Previous work from our laboratory has shown activated Akt and nuclear 
accumulation of β-catenin in NPC clinical samples and NPC xenografts (16).  Infection of 
epithelial cells by the rhesus LCV has also been detected in immunosuppressed macaques 
(11).  SIV infected, immunosuppressed LCV infected macaques also develop B cell 
lymphomas and oral lesions resembling oral hairy leukoplakia (9, 11).  The data presented 
here suggest that Rh-L2A may also contribute to these pathologies. 
 In summary, these data indicate Rh-L2A can phosphorylate and activate Akt, 
phosphorylate and inactivate GSK3β, enable accumulation and nuclear translocation of β-
catenin, and inhibit differentiation in epithelial cells.  The activation of Akt is critical for the 
nuclear accumulation and translocation of β-catenin but is not required for the inhibition of 
differentiation by of Rh-L2A and Rh-L2A∆C.  Importantly, this study also reveals that at 
least six transmembrane domains that are deleted in Rh-L2A∆C are not required for these 
properties.  These data prove analogous properties of EBV LMP2A and Rh-L2A and further 
validate the rhesus macaque model for the study of EBV pathogenesis. 
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ABSTRACT 
Epstein-Barr virus (EBV) is closely associated with several cancers including the highly 
metastatic nasopharyngeal carcinoma (NPC).  A critical step in tumor metastasis is the 
degradation of the basement membrane and extracellular matrix which is mediated by a 
group of proteins known as matrix metalloproteinases (MMPs).  This study shows that EBV 
LMP2A, which is expressed in NPC, increases the expression and activity of MMP-2, MMP-
7, and MMP-13 in human epithelial cells.  The inhibition of the PI3K/Akt pathway led to 
reduced RNA levels and decreased activity of both MMP-7 and MMP-13, but not MMP-2.  
In contrast, the inhibition of the MAPK pathway led to decreased RNA levels and activity of 
MMP-2, but had no effect on MMP-7 or MMP-13.  β-catenin bound the respective Tcf and 
Lef sites in the MMP-7 and MMP-13 promoters, but did not bind the MMP-2 promoter. 
These data indicate that EBV LMP2A can activate several MMPs through the activation of 
both the PI3K/Akt and MAPK pathways and may contribute to NPC invasiveness and 
metastasis through the induction of MMP-2, -7, and -13 transcription and enzymatic activity. 
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INTRODUCTION 
Epstein-Barr virus (EBV), a γ-herpesvirus, is a ubiquitous pathogen that infects 
greater than 90% of the adult human population.  EBV is a well established tumor virus as it 
is causally associated with several types of cancer including Hodgkin lymphoma, endemic 
Burkitt’s lymphoma, and nasopharyngeal carcinoma (NPC).  EBV is strongly associated with 
NPC as it is consistently detected in episomal form in tumors (12).  Specific viral gene 
products expressed in NPC include EBNA1, LMP1, and LMP2A.  LMP2A is often co-
expressed with LMP1 and transcription of both genes is regularly detected in NPC.  
Additionally, high titers of antibodies against LMP2A have been detected in NPC patients, 
which suggest its expression at the protein level (6).   
EBV LMP2A has previously been shown to have striking properties in epithelial cells 
where its expression in the human keratinocyte cell line, HaCaT, induced PI3K activation 
and the subsequent phosphorylation and activation of Akt (13).  In addition, HaCaT cells 
expressing EBV LMP2A had impaired differentiation when grown in organotypic raft 
cultures.  In human telomerase immortalized human foreskin keratinocytes, HFK cells, 
LMP2A expression activated both the PI3K/Akt signaling and Wnt/β-catenin signaling 
pathways.  The activation of these pathways led to the subsequent phosphorylation and 
inactivation of the Akt target GSK3β.  The effects on these pathways also increased the 
levels and induced the nuclear translocation of β-catenin resulting in the activation of TCF 
mediated transcription (8).  In HFK cells, EBV LMP2A also inhibited epithelial cell 
differentiation in assays where differentiation was induced by suspension in methylcellulose.  
In these assays, involucrin and keratinocyte transglutaminase increase during differentiation 
and these increases were blocked by EBV LMP2A (9). 
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NPC is a highly metastatic and invasive tumor associated with EBV.  Although NPC 
ranges from well-differentiated keratinizing squamous cell carcinoma to undifferentiated 
non-kertatinizing carcinoma, the undifferentiated variety is consistently associated with 
EBV. Critical steps in tumor invasion and metastasis are the degradation of the basement 
membrane (BM) and extracellular matrix (ECM).  Numerous proteolytic enzymes degrade 
components of the BM and ECM, including matrix metalloproteinases (MMPs) (10).  MMPs 
are a family of zinc-dependent proteinases that consists of 23 members in humans and taken 
together, can degrade all components of the ECM.  MMPs are translated as zymogens and 
contain a signal sequence targeting them for secretion.  MMPs are classified into five-
subgroups, based on their substrate specificity.  These groups are the collagenases (MMP-1, -
8, -13, -18), gelatinases (MMP-2, -9), stromelysins (MMP-3, -10, -11), matrilysins (MMP-7, 
-26), and membrane type MMPs (MMPs 14-17 and MMPs 24-25) (16).  Increased MMP 
activity has been demonstrated for several herpes viruses including EBV and KSHV.  One 
study in epithelial cells showed that MMP-9 was induced by the EBV oncoprotein LMP1, 
while another demonstrated significant correlation between MMP-9 and LMP1 in NPC 
samples, and this increased expression of MMP-9 was associated with lymph node metastasis 
(4, 15).  For KSHV, it was shown that the K1 protein, the KSHV homolog of LMP1, induced 
MMP-9 expression and activity in endothelial cells (17). 
To determine the effects of LMP2A expression in epithelial cells on MMP expression 
and activity, LMP2A was expressed in immortalized human foreskin keratinocytes (HFK).  
In this system, LMP2A expression increased the expression of MMP-2, -7, and -13.  This 
increased expression correlated with increased activity as determined by gelatin zymography.  
In order to delineate which signal transduction pathways were involved in MMP expression 
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and activity, cells expressing LMP2A were treated with several chemical inhibitors of the 
PI3K/Akt and MAPK pathways.  The inhibition of PI3K/Akt pathway led to decreased 
expression and activity of MMP-7 and MMP-13, but not MMP-2.  Conversely, the inhibition 
of the MAPK pathway led to decreased expression and activity of MMP-2, but not MMP-7 
or MMP-13.  ChIP analysis revealed β-catenin bound the MMP-7 and MMP-13 promoters 
via their respective Tcf/Lef sites but did not bind the MMP-2 promoter.  These data indicate 
that LMP2A activates several MMPs via two distinct signal transduction pathways.  This 
activation suggests LMP2A plays a critical role in the development of EBV associated 
nasopharyngeal carcinoma. 
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RESULTS 
LMP2A expression in HFK cells increases MMP gene and protein expression.  Although 
previous work has shown LMP1 and BZLF1 to increase MMP-9 expression in C33A 
epithelial cells (15, 21), no other publications to date have investigated the potential role of 
LMP2A in the induction of MMP expression. To determine whether LMP2A expression in 
HFK cells increased levels of MMPs, we first generated HFK cells stably expressing HA-
tagged LMP2A in the pBabe vector or vector alone.  Western blot analysis confirmed the 
expression of LMP2A (Figure 1).  Next we performed microarray analysis to determine 
differences in MMP levels of LMP2A expressing cells compared to cells expressing vector 
alone.  As shown in Table 1, we observed approximately a four-fold increase in the levels of 
MMP-2, -7, and -13 in the LMP2A expressing cells compared to vector alone. 
 
 
Figure 1 and Table 1:  Expression of EBV LMP2A in human foreskin keratinocytes.  HFK 
cells were transduced with the pBabe (vector) retrovirus alone or expressing HA-tagged 
LMP2A.  Transduced cells were placed under puromycin selection and expression was 
determined by Western blot using an anti-HA antibody. 
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To confirm the results observed in the array, we performed quantitative, real-time RT-PCR.  
As depicted in Figure 2A, MMP-2, -7, and -13 levels were increased in the LMP2A 
expressing HFK cells compared to vector alone.  RNA levels for each MMP were increased 
approximately four-fold, which correlates with the data obtained from the microarray 
analysis.  In order to determine increased protein levels of each MMP, we performed 
Western blot analysis on TCA precipitated supernatants from both pBabe and pBabe-LMP2A 
expressing cells (Figure 2B).  In the TCA precipitated supernatants, all three MMPs were 
detected in the pBabe-LMP2A supernatants.  These results indicate that EBV LMP2A 
induces MMP expression and secretion in epithelial cells. 
 
 
Figure 2:  MMP RNA levels and protein secretion are increased in HFK-LMP2A cells.  (A) 
Graph of qRT-PCR results showing increased MMP RNA in LMP2A expressing 
cells.  Graph represents the results of four independent experiments performed in 
triplicate.  Error bars represent standard deviation.  (B)  TCA precipitation of HFK 
supernatants.  Supernatants from HFK-pBabe and LMP2A cells were treated with 
TCA and precipitate was subjected to Western blot analysis for the presence of 
MMP-2, -7, and -13. 
 
 99 
LMP2A induces MMP activity in HFK cells. 
MMPs are typically translated as an inactive enzyme (proMMP) and contain a signal 
sequence for targeting to the secretory vesicles.  To determine the gelatinolytic activity of 
MMP-2, -7, and -13 in HFK cells expressing LMP2A, we performed gelatin zymography on 
supernatants from HFK cells expressing either LMP2A or vector alone.  As seen in Figure 3, 
clear bands appear at the appropriate sizes for MMP-2, -7, and -13 (72kDa, 20kDa, and 
48kDa respectively), in the lane contained the LMP2A supernatants indicating that each 
MMP is able to digest the gelatin in the gel.  These results indicate that MMP-2, -7, and -13 
are active in LMP2A expressing cellular supernatants. 
 
 
Figure 3:  MMP activity is induced in HFK-LMP2A cells.  Supernatants from HFK-pBabe 
and LMP2A cells were used to perform gelatin zymography.  Clear band indicates the 
digestion of gelatin by an active MMP. 
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The PI3K/Akt pathway regulates MMP-7 and MMP-13 activity. 
MMP-7 and MMP-13 are regulated by the binding of β-catenin to Tcf/Lef sites in their 
promoters (1, 2, 22).  Since EBV LMP2A has critical effects on β-catenin nuclear 
localization in epithelial cells and this effect is regulated by PI3K/Akt (8), we investigated 
the role of the PI3K/Akt pathway in the activation of MMPs.  To determine the role of 
PI3K/Akt in MMP expression in LMP2A expressing HFK cells, we treated cells with a PI3K 
inhibitor, LY294002 (LY), and an Akt inhibitor, triciribine (TCN) and then performed qRT-
PCR to determine the effects of each inhibitor on MMP RNA levels.  As depicted in Figure 
4A, the LY and TCN inhibitors reduced the levels of MMP-7 and MMP-13 RNA in LMP2A 
expressing cells to nearly control cell levels.  However, MMP-2 RNA levels were not 
affected by either the LY or TCN inhibitors.  Next we performed gelatin zymography to 
determine the effects of the inhibitors on LMP2A mediated gelatinolytic activity.  Both the 
LY and TCN inhibitors abolished MMP-7 and MMP-13 activity while not affecting MMP-2 
activity (Figure 4B).  To show the efficacy of the LY and TCN inhibitor treatments, we 
performed Western blot analysis to determine the phosphoylation status of Akt.  As depicted 
in Figure 4C, phosphorylated Akt is detected in the untreated cells, but not seen in the 
inhibitor treated samples.  These data indicate that the PI3K/Akt pathway is critical for 
MMP-7 and MMP-13 activity but not involved in the regulation of MMP-2 activity. 
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Figure 4:  MMP-7 and MMP-13 RNA levels and activity are regulated by PI3K/Akt.  (A) 
Graph of qRT-PCR results showing decreased MMP-7 and MMP-13 RNA levels in 
LMP2A expressing cells treated with PI3K/Akt inhibitors.  Graph represents the 
results of three independent experiments performed in triplicate.  Error bars represent 
standard deviation.  (B)  Supernatants from HFK-pBabe and LMP2A cells treated 
with PI3K/Akt inhibitors were used to perform gelatin zymography.  Clear band 
indicates the digestion of gelatin by an active MMP.  (C)  Western blot of HFK-
pBabe and LMP2A cells treated with PI3K/Akt inhibitors.  Absence of p-Akt band in 
inhibitor lanes indicates the functionality of the inhibitor.  Total Akt served as a 
loading control. 
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MMP-2 is regulated by MAPK in HFK-LMP2A cells. 
Since several previous reports have implicated the MAPK target Erk in the regulation of 
MMP-2 (5, 7), we decided to pursue the role of the pathway in LMP2A mediated induction 
of MMP-2.  First, we performed qRT-PCR on HFK cells expressing both LMP2A and vector 
alone treated with PD98059 (PD), a MAPK inhibitor or DMSO as a vehicle control to 
determine if inhibition of Erk would affect RNA levels of MMP-2.  As seen in Figure 5A, 
treatment with PD reduced MMP-2 RNA levels in LMP2A cells to nearly vector alone 
levels.  Of note, there was no effect on MMP-7 or MMP-13 RNA levels in cells treated with 
PD.  Next we performed gelatin zymography on supernatants treated with PD or DMSO to 
determine changes in MMP-2 activity.  As seen in Figure 5B, MMP-2 activity was ablated in 
PD treated LMP2A supernatants whereas no effect on MMP-7 or MMP-13 activity was 
observed.  To show the efficacy of the PD inhibitor treatment, we performed Western blot 
analysis to determine the phosphoylation status of Erk.  As depicted in Figure 5C, 
phosphorylated Erk is detected in the untreated cells, but not seen in the inhibitor treated 
samples.  These data indicate that the MAPK pathway is important for MMP-2 regulation, 
but is not involved in the regulation of MMP-7 or MMP-13. 
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Figure 5:  MMP-2 RNA levels and activity are regulated by MAPK.  (A)  Graph of qRT-
PCR results showing decreased MMP-2 RNA levels in LMP2A expressing cells treated with 
a MAPK inhibitor.  Graph represents the results of three independent experiments performed 
in triplicate.  Error bars represent standard deviation.  (B)  Supernatants from HFK-pBabe 
and LMP2A cells treated with a MAPK inhibitor were used to perform gelatin zymography.  
Clear band indicates the digestion of gelatin by an active MMP.  (C)  Western blot of HFK-
pBabe and LMP2A cells treated with MAPK inhibitor.  Absence of p-Erk band in inhibitor 
lanes indicates the functionality of the inhibitor.  Total Erk served as a loading control. 
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β-catenin immunoprecipitates on the MMP-7 and MMP-13 promoters.  Previous studies 
indicated that β-catenin can regulate MMP-7 and MMP-13 at the transcriptional level by 
binding either a Tcf-4 or Lef-1 site in their respective promoters (1, 2, 22).  Since LMP2A is 
known to induce β-catenin nuclear translocation in epithelial cells, we hypothesized β-
catenin would strongly bind the MMP-7 and MMP-13 promoters in LMP2A expressing cells.  
To validate this hypothesis, HFK cells stably expressing LMP2A or pBabe vector alone were 
analyzed by ChIP using primers flanking the Tcf-4 site in the MMP-7 promoter and primers 
flanking the Lef-1 site in the MMP-13 promoter.  The precipitation with β-catenin strongly 
detected the Tcf-4 and Lef-1 sites in the MMP-7 and MMP-13 promoters in both pBabe and 
LMP2A cells with the stronger detection of each site visible in LMP2A expressing cells 
(Figure 6A).  In addition, β-catenin binding to the MMP-2 promoter was not detected.  In 
order to evaluate the results of the ChIP, we performed qRT-PCR on the ChIP products.  As 
depicted in Figure 6B, the binding of β-catenin to the MMP-7 and MMP-13 promoters was 
increased approximately two fold in LMP2A expressing cells, whereas MMP-2 promoter 
binding was not detected.  Of note, previous work from our laboratory has shown nuclear β-
catenin levels to be increased approximately two-fold in LMP2A expressing cells (8).  These 
data indicate that LMP2A regulates MMP-7 and MMP-13 by increasing nuclear β-catenin 
which subsequently interacts with Tcf and Lef sites on the MMP promoters inducing 
transcription. 
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Figure 6:  LMP2A increases binding of β-catenin to MMP-7 and MMP-13 promoters.  (A) 
ChIP analysis using mouse IgG1 (isotype control), H3 histone (positive control) or β-catenin 
in HFK-pBabe and HFK-LMP2A expressing cells.  Precipitated complexes were subjected to 
PCR with primer pairs specific to the Tcf4 and Lef1 sites in the MMP-7 and MMP-13 
promoters, respectively.  PCR was also performed on chromatin input (lanes 4-9).  (B)  
Graphical depiction of qRT-PCR results on ChIP products.  Real-time quantitative PCR was 
performed on precipitated DNA using primers specific for the TCF/LEF promoter regions of 
the MMP-7 and MMP-13 gene and for the promoter region of the MMP-2 gene.  Values are 
normalized against the input DNA and are represented as the percentage of input for each 
given sample.  Each value represents the mean of three independent measurements of the 
precipitated DNA. 
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DISCUSSION 
This study reveals that LMP2A increases the expression and activity of MMP-2, -7, and -13 
in epithelial cells.  In LMP2A expressing HFK cells, the expression and activity of both 
MMP-7 and MMP-13, but not MMP-2, were directly related to the activation of the 
PI3K/Akt pathway.  The expression and activity of MMP-2 was directly related to the 
activation of the MAPK pathway and the inhibition of this pathway had no effect on the 
levels or activity of MMP-7 or MMP-13. 
Previous work from our laboratory has shown LMP2A to have profound effects on β-catenin 
localization in epithelial cells (8).  In LMP2A expressing epithelial cells, β-catenin 
accumulates in the cytoplasm and subsequently translocates to the nucleus in an Akt 
dependent manner.  Once in the nucleus, β-catenin can bind members of the T cell factor 
(TCF)/lymphoid enhancing factor (LEF) family of transcription factors to induce target gene 
expression.  With regards to MMP-7, β-catenin has been shown to regulate MMP-7 
expression by binding a TCF-4 site in the promoter (1, 2).  Additionally, β-catenin can bind a 
LEF-1 site in the MMP-13 promoter resulting in activation (22).  Therefore, it is reasonable 
that LMP2A would increase both the levels and activity of MMP-7 and MMP-13.  
In the case of MMP-2, the activation of ERK is critical for MMP-2 function in brain cancer 
metastasis (7).  Furthermore, the phosphorylation of ERK is necessary for MMP-2 activation 
and subsequent cell invasion in fibrosarcoma cells (5).  LMP2A has been shown to interact 
with ERK and increase ERK phosphorylation in B cells (11).  It is not surprising LMP2A 
modulates MMP-2 activity as MMP-2 is consistently associated with NPC (18, 19) and 
MMP-2 activity is not related to LMP1 expression (20). 
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Although previous studies have shown roles for other EBV proteins such as LMP1 and 
BZLF1 in the induction of MMPs in epithelial cells and NPC (14, 15, 20, 21), this is the first 
study to date that implicates LMP2A in the activation of MMPs in epithelial cells.  Since 
NPC is a highly metastatic tumor that regularly expresses LMP2A, the activation of MMP-2, 
-7, and -13 may be a critical factor contributing to pathogenesis. 
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MATERIALS AND METHODS 
 
Cell culture and retrovirus production.  HFK cells (3) were maintained in keratinocyte 
serum free medium (K-SFM, Gibco) supplemented with epidermal growth factor (.2ng/ml), 
bovine pituitary extract (30µg/ml), and 1% antibiotic-antimycotic solution (Sigma) and 
grown in a humidified incubator at 37°C and 5% CO2.  Stable cell lines were generated using 
recombinant retrovirus expressing either the pBabe vector or pBabe vector subcloned with 
hemagglutinin (HA) tagged LMP2A as previously described (13) and used to transduce HFK 
cells.  A stable pool of HFK cells expressing either pBabe or pBabe-LMP2A was selected 
using K-SFM media containing puromycin (Sigma) at .5µg/ml. 
 
Western blot analysis and antibodies.   Whole cell lysates were prepared using Nonidet P-
40 (NP-40) lysis buffer containing 50mM Tris-HCl, 150mM NaCl, 2mM EDTA, 10% 
glycerol, 1% NP-40, 1mM sodium vanadate (Na3VO4), 0.4mM phenylmethylsulfonyl 
fluoride (PMSF), and protease and phosphatase cocktails (Sigma) at 1:100.  Protein 
concentrations were determined using the Bio-Rad DC assay system according to 
manufacturer’s instructions.  Lysates were boiled in a protein loading solution containing 
SDS and β-mercaptoethanol for five minutes and subjected to SDS-10% polyacrylamide gel 
electrophoresis.  Proteins were transferred to an Optitran nitrocellulose membrane 
(Schleicher & Schuell) and subjected to Western blot analysis.  Antibodies used include anti-
HA from Covance, anti-MMP-2 and MMP-13 from Calbiochem, and anti-MMP-7 from 
Santa Cruz.  Horseradish peroxidase secondary antibodies (Amersham) and SuperSignal 
West Pico System (Pierce) were used to detect antibody bound proteins. 
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TCA protein precipitation.  Supernatants from cells expressing pBabe or pBabe-LMP2A 
were harvested and 100% TCA was added at a ratio of 1 volume of TCA to 4 volumes of 
sample.  Samples were then incubated for 10 minutes at 4°C and then spun at high speed to 
pellet the protein.  Supernatant was then removed and pellet washed with cold acetone three 
times.  Pellet was then dried to remove any excess acetone before pellet was resuspended in 
3X protein loading solution for running on SDS-PAGE. 
 
Gelatin zymography.  Supernatants from cells expressing either pBabe or pBabe-LMP2A 
were fixed with SDS loading buffer [50mM Tris-HCl (pH 6.8), 10% glycerol, 1% SDS, and 
0.01% bromophenol blue] followed by a 20 minute incubation at 37°C.  Fixed supernatants 
were then electrophoresed on a 10% SDS-PAGE gel containing gelatin (Sigma) at a final 
concentration of 0.1%.  Gel was then rinsed with PBS containing 2.5% Triton X-100 for two 
hours.  Again, the gel was rinsed with water to remove the Triton and incubated overnight at 
37°C in a solution containing 50mM Tris-HCl (pH 7.6), 150mM NaCl, 10mM CaCl2, and 
0.02% NaN3.  The gel was then stained in 0.1% Coomassie blue R250 (Sigma) dissolved in 
40% methanol and 10% acetic acid.  To destain the gel, a solution containing 40% methanol 
and 10% acetic acid was used.  The MMPs are identified as clear bands against the dark 
background of stained gel.  Gel was scanned using a Typhoon 9400 scanner. 
 
Inhibitor experiments.  For qRT-PCR and gelatin zymography experiments, HFK cells 
were plated in 100mm dishes containing keratinocyte media.  Within 24h post-seed, 
triciribine (TCN), LY294002, and PD98059 (Calbiochem) were added to the media at a 
concentration of 5µM and 10µM respectively.  Control plates were treated with an equivalent 
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volume of DMSO (vehicle control).  After 24-36h of inhibitor treatment, cells or 
supernatants were harvested for RNA isolation, gelatin zymography, or Western blot 
analysis.  
  
Microarray analysis. Total RNA was extracted from HFK cells expressing LMP2A or 
vector alone using a RNeasy kit (Qiagen) according to manufacturer’s instructions. RNA 
concentration was determined by NanoDrop and the quality of RNA checked by using an 
Agilent LabChip Bioanalyzer to ensure high-quality RNA for successful hybridization.  
Human 1A (V2) chips containing oligonucleotides representing 22K human genes were 
obtained from Agilent Technologies. Total RNA samples were amplified using T7 primers to 
make cRNA. The cRNA samples were incorporated with two different Cy dyes (Cy3 and 
Cy5) and hybridized with the microarray. Slides were scanned using an Axon 4000 scanner 
and images processed with GenePix software to generate raw data files for uploading to the 
University of North Carolina Microarray Database for normalization.  Clustering analysis 
was performed within the database and data sets were combined in Microsoft Excel for 
sorting. 
 
Quantitative real-time PCR.  RNA from HFK cells expressing pBabe or pBabe-LMP2A 
was extracted using a RNeasy kit (Qiagen) according to manufacturer’s instructions.  
Quantitative PCR was performed using QuantiTect SYBR Green kit (Qiagen) with the 
following specific primers:  human MMP-7 (forward, 5´-GACATCATGATTGGCTTTGC-
3´; reverse, 5´-GTGAGCATCTCCTCCGAGAC-3´), human MMP-13 (forward, 5´-
AGCACCCTTCTCATGACCTC-3´; reverse, 5´-TCTTTTGGAAGACCCAGTTCA-3´), 
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human MMP-2 (forward, 5´-ATGGCAAGTACGGCTTCTGT-3´; reverse, 5´-
CATAGGATGTGCCCTGGAAG-3´), and as an internal control, actin (forward, 5´-
CCCAGCACAATGAAGATCAA-3´; reverse, 5´-ACATCTGCTGGAAGGTGGAC-3´). 
Amplification of target sequences was detected with an ABI 7900HT detection system 
(Applied Biosystems) and analyzed with SDS 2.0 software (Applied Biosystems).  PCR 
conditions were as follows:  One cycle for 30 minutes at 50°C for reverse transcription, one 
cycle for 10 minutes at 95°C for initial activation, followed by 40 cycles of 95°C for 15 
seconds, 55°C for 15 seconds, and 72°C for 30 seconds followed by a dissociation curve 
cycle.  Raw data was normalized to actin according to the Applied Biosystems manual. 
 
Chromatin Immunoprecipitations.  ChIPs were performed using the EZ ChIP kit (Upstate) 
according to manufacturer’s instructions.  In brief, 1 x 107 cells in 10ml of media were cross-
linked in 1% formaldehyde at room temperature for 15 minutes followed by quenching with 
glycine.  Cells were then washed in PBS and then harvested in PBS containing protease 
inhibitor, spun, and cell pellet was then lysed in SDS lysis buffer containing protease 
inhibitor.  Lysates were sonicated, clarified, and pre-cleared with Protein G agarose.  
Supernatants were incubated without antibody or with β-catenin antibody and nutated 
overnight at 4°C.  Lysates were immunoprecipitated with Protein G agarose for one hour and 
beads subsequently washed with a series of buffers.  DNA/protein was eluted from the beads 
using elution buffer.  Cross-linking was reversed at 65°C overnight in the presence of NaCl.  
Samples were then treated with RNase A for 30 minutes at 37°C and Proteinase K for 2 
hours at 45°C.  Sample DNA was purified using a nucleotide removal kit (Qiagen) as 
directed by the manufacturer.  The Tcf4 site on the MMP-7 promoter was PCR amplified 
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using the primer set forward, 5´-AGCCCAAAATGGACTTCCAA-3´; reverse, 5´-
CATCAAATGGGTAGGAGTCC-3´.  The Lef1 site on the MMP-13 promoter was amplified 
with the primers forward, 5´-CATGCCAACAAATTCCATATTG-3´; reverse, 5´-
CCAGCCACGCATAGTCATATAG-3´.  The primer set used to amplify the MMP-2 
promoter was forward, 5´-ACTTCCTCAGGCGGTGGCTG-3´; reverse, 5´-
GTTGGAGCCTGCTCCGCGGC-3´. PCRs were performed using Hot Start Taq (Qiagen) 
under standard conditions. 
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GENERAL CONCLUSIONS 
 
 Although the vast majority of EBV infections are asymptomatic, the ubiquitous 
nature of the virus allows for a significant number of individuals to develop EBV-associated 
diseases and malignancies.  The substantial morbidity and mortality associated with EBV 
infection necessitates further study of the virus and its pathogenesis to properly develop and 
design effective therapies to combat this insidious infectious agent. 
 The two principle cells types infected by EBV are B lymphocytes and epithelial cells.  
Both lytic and latent phases of infection occur in B lymphocytes.  Notably, this latent 
reservoir in the B cell compartment enables viral survival and persistence in the host.  
Epithelial cell infection has largely been associated with the lytic phase and production of 
progeny enabling the horizontal spread to the next host via salivary shedding or for infection 
of trafficking B lymphocytes in the area.  However, EBV-associated malignancies of 
epithelial origin are primarily associated with latent infection.  EBV infected malignant cells 
are clonal with respect to the virus, the viral genome is episomal in form, and viral gene 
expression is normally restricted to the latent genes (24). 
 The purpose of the current study was to further evaluate the role of EBV LMP2A and 
the rhesus EBV LMP2A homolog in epithelial cells.  In contrast to epithelial cells, the vast 
majority of studies investigating the consequences of LMP2A expression have focused on B 
lymphocytes.  In B lymphocytes, LMP2A is responsible for maintaining latency (15-18).  
LMP2A blocks BCR activation and signaling by absorbing BCR-associated signaling 
molecules and manipulating their turnover in addition to blocking BCR translocation into 
lipid rafts which prevents the initiation of signaling (6, 12, 31).  Additionally, studies with 
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LMP2A transgenic mice revealed that LMP2A transmits survival signals in B lymphocytes, 
alters global B lymphocyte transcription, and allows B lymphocytes to circumvent normal 
developmental checkpoints to colonize the periphery (2, 3, 23).  Clearly, much effort has 
been invested in elucidating the function of LMP2A in B lymphocytes.  However, the role of 
LMP2A expression in epithelial cells is only beginning to unfold. 
 Several previous studies from our lab focused on the role of LMP2A expression in 
epithelial cells.  One study in the HaCaT human keratinocyte cell line showed that LMP2A 
expression activated the PI3K/Akt signaling pathway, conferred anchorage independent cell 
growth, and tumorigenicity in nude mice (25).  Studies continued using more “normal” 
telomerase immortalized human foreskin keratinocytes, known as HFK cells.  Studies in 
HFK cells revealed LMP2A activated PI3K/Akt, as observed in HaCaT cells. The same study 
showed two Akt targets, GSK3β and FKHR were phosphorylated and subsequently 
inactivated in LMP2A expressing HFK cells.  LMP2A expression in HFK cells resulted in 
cytoplasmic accumulation of β-catenin, PI3K dependent nuclear translocation of β-catenin, 
and activation of a TCF responsive reporter (20).  Additional study identified key domains in 
LMP2A that are important for its effects on PI3K/Akt and β-catenin signaling.  The ITAM 
motif was critical for Akt activation in epithelial cells and both the ITAM and PY motifs 
contributed to the effects of LMP2A on β-catenin signaling (21).  In regards to epithelial cell 
biology, LMP2A was shown to inhibit epithelial cell differentiation.  We have continued 
these studies of EBV LMP2A as well as initiated study of the rhesus LMP2A homolog in 
HFK cells. 
 The work presented in chapter two revealed that rhesus LMP2A expression in HFK 
cells activates PI3K/Akt, phosphorylates and inactivates the Akt target GSK3β, and allows 
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for the accumulation and nuclear translocation of β-catenin in an Akt dependent manner.  
Additionally, rhesus LMP2A was able to inhibit differentiation in epithelial cells.  Notably, a 
mutant form of rhesus LMP2A lacking the last six transmembrane domains of the protein 
functioned similarly to wild-type rhesus LMP2A.  These results indicate that the rhesus 
LMP2A homolog functions in a similar fashion to EBV LMP2A and underscores the 
suitability of the rhesus macaque model for the study of EBV pathogenesis. 
 Data presented in chapter three also revealed an important effect of LMP2A on 
epithelial cell biology and potential role in NPC metastasis.  Although other EBV proteins 
such as LMP1 and BZLF1 have been shown to increase MMP activity, no previously 
published report indicated a role for LMP2A in increased MMP activity (11, 27, 28, 33, 34).  
Experiments indicated that LMP2A induced MMP-2, -7, and -13 expression and activity in 
HFK cells as indicated by microarray, qRT-PCR, and gelatin zymography.  Additionally, 
MMP-2 activity was dependent on MAPK activation whereas MMP-7 and MMP-13 activity 
was dependent on PI3K/Akt activation.  Notably, MMP-7 and MMP-13 are known TCF/LEF 
targets.  ChIP results indicated that β-catenin did bind the TCF/LEF sites in the MMP-7 and 
MMP-13 promoters.  These findings support previous results showing LMP2A expression in 
HFK cells activated a TCF responsive promoter (20).  These effects of LMP2A in epithelial 
cells may provide a mechanism by which EBV-associated NPC metastasizes to the lymph 
nodes. 
 Overall, these data contribute to the expanding knowledge of pathogenesis 
mechanisms employed by EBV in the development of disease and malignancy.  In epithelial 
cells, both EBV and LCV LMP2A can activate the PI3K/Akt and β-catenin pathways.  The 
PI3K/Akt pathway is aberrantly activated in many types of cancers including lymphomas, 
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melanomas, and breast and prostate carcinomas.  β-catenin is at the crux of the Wnt signaling 
pathway which is abnormally activated in over 90% of colon carcinomas as well as in an 
array of other malignancies.  Aberrant activation of these pathways by LCV and EBV 
LMP2A allows cells to continually proliferate and survive, primed for transformation.  
Additionally, inhibition of epithelial cell differentiation by LCV LMP2A may further enable 
these processes to occur by maintaining a metabolically active host cell population.  Notably, 
EBV and LCV are not the only viruses known to target the PI3K/Akt and β-catenin 
pathways.  Another herpesvirus, KSHV and the human polyomavirus, JC virus have been 
shown to activate these pathways (8, 9, 19, 29).  More recently, multiple studies have found 
that influenza A, poliovirus, human rhinovirus, hepatitis B, and rotavirus can all activate the 
PI3K/Akt pathway (1, 10, 13, 22, 26).   
 The upregulation of MMPs by EBV LMP2A is another potential mechanism by 
which EBV can enable tumorigenesis and metastasis.  MMP overexpression has been 
associated with various cancers including colon, breast, bladder, and lung (5).  In many 
instances this increased MMP expression is associated with an invasive and metastatic 
phenotype.  As both LMP1 and LMP2A are both consistently expressed in NPC and both can 
activate MMPs, it is likely that these two proteins act additively or synergistically to enable 
NPC metastasis to secondary sites such as the lymph nodes.  Of note, other viruses have been 
shown to activate MMPs.  KSHV, a related herpesvirus, has been shown to activate MMP-9 
in endothelial cells (30).  Viruses such as dengue, human papilloma virus (HPV), and 
coxsackievirus B3 have also recently been shown to activate MMPs during infection (4, 14, 
32). 
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 In conclusion, these studies have identified key pathways targeted by LCV and EBV 
LMP2A in epithelial cells.  LCV LMP2A activates the PI3K/Akt pathway and the Akt target, 
GSK3β, is phosphorylated and inactivated in LCV LMP2A expressing keratinocytes.  
Furthermore, LCV LMP2A expression in HFK cells results in the cytoplasmic accumulation 
of β-catenin with Akt dependent nuclear translocation, indicating activation of the β-catenin 
signaling pathway.  LCV LMP2A was also able to inhibit differentiation in epithelial cells.  
Importantly, a mutant LCV LMP2A lacking six transmembrane domains was able to function 
similarly to full-length LCV LMP2A.  EBV LMP2A was found to increase expression and 
activity of MMP-2, -7, and -13.  The EBV LMP2A effects on MMP-2 were dependent on the 
MAPK pathway, whereas MMP-7 and MMP-13 activity were dependent on PI3K/Akt 
activation.  These studies have contributed to our understanding of LCV and EBV biology in 
epithelial cells by providing validation for the rhesus macaque model in the study of EBV 
pathogenesis and insight into the mechanisms of EBV-associated diseases and malignancies. 
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